



(51) International Patent Classification:

A61K 9/70 (2006.01) A61K 31/085 (2006.01)

(21) International Application Number:

PCT/US2018/053042

(22) International Filing Date:

27 September 2018 (27.09.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

15/717,859 27 September 2017 (27.09.2017) US  
15/791,249 23 October 2017 (23.10.2017) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US 15/791,249 (CIP)  
Filed on 23 October 2017 (23.10.2017)  
US 15/717,859 (CIP)  
Filed on 27 September 2017 (27.09.2017)

(71) Applicant: AQUESTIVE THERAPEUTICS, INC.  
[US/US]; 30 Technology Drive, Warren, NJ 07059 (US).

(72) Inventors: SCHOBEL, Alexander, Mark; 6 Dermott Drive, Whitehouse Station, NJ 08889 (US). VARJAN, Stephanie, Marie; 151 Prospect Avenue, Oradell, NJ

07649 (US). WARGACKI, Stephen, Paul; 17 Indian Creek Rd., Annandale, NJ 08801 (US).


(74) Agent: FOX, Harold, H. et al.; Steptoe & Johnson LLP, 1330 Connecticut Avenue, NW, Washington, DC 20036 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS

(57) Abstract: Pharmaceutical compositions having enhanced active component permeation properties are described.



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

**Published:**

— *with international search report (Art. 21(3))*

## ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS

### CLAIM FOR PRIORITY

This application is a continuation-in-part of U.S. Patent Application No. 15,791,249 filed on October 23, 2017, which is a continuation-in-part of U.S. Patent Application No. 15/717,859, filed September 27, 2017, which is a continuation-in-part of U.S. Patent Application No. 15/587,364, filed May 4, 2017, which claims priority under 35 U.S.C. §119(e) to U.S. Patent Application Serial No. 62/331,996 filed on May 5, 2016, each of which is hereby incorporated by reference in its entirety.

### TECHNICAL FIELD

This invention relates to pharmaceutical compositions.

### BACKGROUND

Active ingredients, such as drugs or pharmaceuticals, are delivered to patients in deliberate fashion. Delivery of drugs or pharmaceuticals using film transdermally or transmucosally can require that the drug or pharmaceutical permeate or otherwise cross a biological membrane in an effective and efficient manner.

### SUMMARY

In general a pharmaceutical composition can include a polymeric matrix, epinephrine in the polymeric matrix, and an adrenergic receptor interacter. Epinephrine can be provided in the form of a prodrug, such as a lipophilic prodrug, for example, dipifevrin. In certain embodiments, the pharmaceutical composition can further include a permeation enhancer. In certain embodiments, an adrenergic receptor interacter can be an adrenergic receptor blocker. In some embodiments, the adrenergic receptor interacter can also be a flavonoid, or used in combination with a flavonoid.

In certain embodiments, the adrenergic receptor interacter can be a terpenoid, terpene or a C3-C22 alcohol or acid. The adrenergic receptor interacter can be a sesquiterpene. In certain embodiments, the adrenergic receptor interacter can include farnesol, linoleic acid, arachidonic acid, docosahexanoic acid, eicosapentanoic acid, or docosapentanoic acid, or combinations thereof.

In certain embodiments, a pharmaceutical composition can include a polymeric matrix, a pharmaceutically active component in the polymeric matrix, and an aporphine alkaloid interacter.

5 In other embodiments, a pharmaceutical composition can include a polymeric matrix, a pharmaceutically active component in the polymeric matrix, and a vasodilator interacter.

In certain embodiments, the pharmaceutical composition can be a film further comprising a polymeric matrix, the pharmaceutically active component being contained in the polymeric matrix.

In certain embodiments, the adrenergic receptor interacter can be a phytoextract.

10 In certain embodiments, the permeation enhancer can be a phytoextract.

In certain embodiments, the permeation enhancer can include a phenylpropanoid.

In certain embodiments, the pharmaceutical composition can include a fungal extract.

In certain embodiments, the pharmaceutical composition can include saturated or unsaturated alcohol.

15 In certain embodiments, the alcohol can be benzyl alcohol.

In some cases, the flavonoid, phytoextract, phenylpropanoid, eugenol, or fungal extract can be used as a solubilizer.

In certain embodiments, the phenylpropanoid can be eugenol. In other embodiments, the phenylpropanoid can be eugenol acetate. In certain embodiments, the phenylpropanoid can be a cinnamic acid. In other embodiments, the phenylpropanoid can be a cinnamic acid ester. In  
20 other embodiments, phenylpropanoid can be a cinnamic aldehyde.

In other embodiments, the phenylpropanoid can be a hydrocinnamic acid. In certain embodiments, the phenylpropanoid can be chavicol. In other embodiments, the phenylpropanoid can be safrole.

25 In certain embodiments, the phytoextract can be an essential oil extract of a clove plant. In other examples, the phytoextract can be an essential oil extract of a leaf of a clove plant. The phytoextract can be an essential oil extract of a flower bud of a clove plant. In other embodiments, the phytoextract can be an essential oil extract of a stem of a clove plant.

In certain embodiments, the phytoextract can be synthetic. In certain embodiments, the  
30 phytoextract can include 20-95% eugenol, including 40-95% eugenol, and including 60-95% eugenol. In certain embodiments, the phytoextract can include 80-95% eugenol.

In certain embodiments, the polymer matrix can include a polymer. The polymer can include a water soluble polymer.

In certain embodiments, the polymer can be a polyethylene oxide.

In certain embodiments, the polymer can be a cellulosic polymer. In certain  
5       embodiments, the cellulosic polymer can be hydroxypropylmethyl cellulose, hydroxyethyl  
cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, methylcellulose,  
carboxymethyl cellulose and/or sodium carboxymethylcellulose.

In certain embodiments, the polymer can include hydroxypropyl methylcellulose.

In certain embodiments, the polymer can include polyethylene oxide and hydroxypropyl  
10       methylcellulose.

In certain embodiments, the polymer can include polyethylene oxide and/or polyvinyl  
pyrrolidone.

In certain embodiments, the polymeric matrix can include polyethylene oxide and/or a  
polysaccharide.

15       In certain embodiments, the polymeric matrix can include polyethylene oxide,  
hydroxypropyl methylcellulose and/or a polysaccharide.

In certain embodiments, the polymeric matrix can include polyethylene oxide, a  
cellulosic polymer, polysaccharide and/or polyvinylpyrrolidone.

In certain embodiments, the polymeric matrix can include at least one polymer selected  
20       from the group of: pullulan, polyvinyl pyrrolidone, polyvinyl alcohol, sodium alginate,  
polyethylene glycol, xanthan gum, tragacanth gum, guar gum, acacia gum, arabic gum,  
polyacrylic acid, methylmethacrylate copolymer, carboxyvinyl copolymers, starch, gelatin,  
ethylene oxide, propylene oxide co-polymers, collagen, albumin, poly-amino acids,  
polyphosphazenes, polysaccharides, chitin, chitosan, and derivatives thereof.

25       In certain embodiments, the pharmaceutical composition can further include a stabilizer.  
Stabilizers can include antioxidants, which can prevent unwanted oxidation of materials,  
sequestrants, which can form chelate complexes and inactivating traces of metal ions that would  
otherwise act as catalysts, emulsifiers and surfactants, which can stabilize emulsions, ultraviolet  
stabilizers, which can protect materials from harmful effects of ultraviolet radiation, UV  
30       absorbers, chemicals absorbing ultraviolet radiation and preventing it from penetrating the  
composition, quenchers, which can dissipate the radiation energy as heat instead of letting it

break chemical bonds, or scavengers which can eliminate free radicals formed by ultraviolet radiation.

In yet another aspect, the pharmaceutical composition has a suitable nontoxic, nonionic alkyl glycoside having a hydrophobic alkyl group joined by a linkage to a hydrophilic saccharide

5 in combination with a mucosal delivery-enhancing agent selected from: (a) an aggregation inhibitory agent; (b) a charge-modifying agent; (c) a pH control agent; (d) a degradative enzyme inhibitory agent; (e) a mucolytic or mucus clearing agent; (f) a ciliostatic agent; (g) a membrane penetration-enhancing agent selected from: (i) a surfactant; (ii) a bile salt; (ii) a phospholipid additive, mixed micelle, liposome, or carrier; (iii) an alcohol; (iv) an enamine; (v) a nitric oxide

10 donor compound; (vi) a long chain amphipathic molecule; (vii) a small hydrophobic penetration enhancer; (viii) sodium or a salicylic acid derivative; (ix) a glycerol ester of acetoacetic acid; (x) a cyclodextrin or beta-cyclodextrin derivative; (xi) a medium-chain fatty acid; (xii) a chelating agent; (xiii) an amino acid or salt thereof; (xiv) an N-acetyl amino acid or salt thereof; (xv) an enzyme degradative to a selected membrane component; (ix) an inhibitor of fatty acid synthesis;

15 (x) an inhibitor of cholesterol synthesis; and (xi) any combination of the membrane penetration enhancing agents recited in (i)-(x); (h) a modulatory agent of epithelial junction physiology; (i) a vasodilator agent; (j) a selective transport-enhancing agent; and (k) a stabilizing delivery vehicle, carrier, mucoadhesive, support or complex-forming species with which the compound is effectively combined, associated, contained, encapsulated or bound resulting in stabilization of

20 the compound for enhanced mucosal delivery, wherein the formulation of the compound with the transmucosal delivery-enhancing agents provides for increased bioavailability of the compound in a blood plasma of a subject.

In general a method of making a pharmaceutical composition can include combining an adrenergic receptor interacter with a pharmaceutically active component including epinephrine

25 or its prodrug, and forming a pharmaceutical composition including the adrenergic receptor interacter and the pharmaceutically active component.

In general, a pharmaceutical composition can be dispensed from a device. A device can include a housing that holds an amount of a pharmaceutical composition, including a polymeric matrix; a pharmaceutically active component including epinephrine in the polymeric matrix; and

30 an adrenergic receptor interacter; and an opening that dispenses a predetermined amount, such as a predetermined dose, of the pharmaceutical composition. The device can also dispense a

pharmaceutical composition including a permeation enhancer including a phenylpropanoid and/or a phytoextract.

In certain embodiments, a pharmaceutical composition can include a polymeric matrix; a pharmaceutically active component in the polymeric matrix; and an interacter that creates  
5 increased blood flow or enables a flushing of the tissue to modify transmucosal uptake of the pharmaceutically active component.

In certain embodiments, a pharmaceutical composition can include a polymeric matrix; a pharmaceutically active component in the polymeric matrix; and an interacter that has a positive or negative heat of solution which are used as aids to modify (increase or decrease)  
10 transmucosal uptake.

In other embodiments, a pharmaceutical composition includes a polymeric matrix, a pharmaceutically active component in the polymeric matrix, and an interacter, the composition contained in a multilayer film having at least one side where the edges are coterminous.

In general, a method of treating a medical condition can include administering an  
15 effective amount of a pharmaceutical composition including a polymeric matrix, pharmaceutically active component including epinephrine in the polymeric matrix, and an adrenergic receptor interacter. The epinephrine can be administered as a prodrug, such as dipivefrin. Thus, a method of treating a medical condition can include administering an effective amount of a pharmaceutical composition including a polymeric matrix, pharmaceutically active  
20 component including dipivefrin in the polymeric matrix, and an adrenergic receptor interacter. In certain embodiments, the medical condition can include hypotension, cardiac arrest, heart failure, anaphylaxis, mydriasis, asystole, pulseless electrical activity, ventricular fibrillation, pulseless ventricular tachycardia, bradycardia, arrhythmia, or asthma exacerbation.

In certain embodiments, a pharmaceutical film can include a polymeric matrix, a  
25 pharmaceutically active component including epinephrine or its prodrug contained in the polymeric matrix and an adrenergic receptor interacter. The pharmaceutical film can have a Tmax of 5-60 minutes, and a Cmax of 0.1 ng/ml-2 ng/ml. In certain embodiments, the Tmax is 40 minutes or less and wherein the Cmax is 0.1 ng/ml or greater. In certain embodiments, the Tmax is 35 minutes or less and wherein the Cmax is 0.15 ng/ml or greater. In certain  
30 embodiments, Tmax is 30 minutes or less and wherein the Cmax is 0.2 ng/ml or greater.

The C<sub>max</sub> can be 0.1 ng/ml- 2 ng/ml, 0.15 ng/ml-25 ng/ml, 0.2 ng/ml- 1.0 ng/ml, 0.2 ng/ml -1.2 ng/ml, and 0.2 ng/ml - 1.3 ng/ml. The C<sub>max</sub> can be greater than 0.1 ng/ml, greater than 0.15 ng/ml, greater than 0.2 ng/ml , greater than 0.4ng/ml, greater than 0.5ng/ml, greater than 1.0ng/ml, greater than 1.2 ng/ml. The C<sub>max</sub> can be less than 3 ng/ml, less than 2 ng/ml and less than 1.5 ng/ml.

The T<sub>max</sub> can be 0-240 minutes, 10-60 minutes, 20-40 minutes, 12-15 minutes, and 5-10 minutes. The T<sub>max</sub> can be less than 25 minutes, less than 20 minutes, 15 minutes, less than 12 minutes, and less than 10 minutes.

Other aspects, embodiments, and features will be apparent from the following description, the drawings, and the claims.

#### BRIEF DESCRIPTION OF THE FIGURES

Referring to **Figure 1A**, a Franz diffusion cell 100 includes a donor compound 101, a donor chamber 102, a membrane 103, sampling port 104, receptor chamber 105, stir bar 106, and a heater/circulator 107.

Referring to **Figure 1B**, a pharmaceutical composition is a film 100 comprising a polymeric matrix 200, the pharmaceutically active component 300 being contained in the polymeric matrix. The film can include a permeation enhancer 400.

Referring to **Figures 2A and 2B**, the graphs show the permeation of an active material from a composition.

Referring to **Figure 2A**, this graph shows average amount of active material permeated vs. time, with 8.00 mg/mL epinephrine bitartrate and 4.4 mg/mL epinephrine base solubilized.

Referring to **Figure 2B**, this graph shows average flux vs. time, with 8.00 mg/mL epinephrine bitartrate and 4.4 mg/mL epinephrine base solubilized.

Referring to **Figure 3**, this graph shows ex-vivo permeation of epinephrine bitartrate as a function of concentration.

Referring to **Figure 4**, this graph shows permeation of epinephrine bitartrate as a function of solution pH.

Referring to **Figure 5**, this graph shows the influence of enhancers on permeation of epinephrine, indicated as amount permeated as a function of time.



Referring to **Figure 6A** and **6B**, these graphs show the release of epinephrine on polymer platforms (6A) and the effect of enhancers on its release (6B), indicated as amount permeated (in  $\mu\text{g}$ ) vs. time.

Referring to **Figure 7**, this graph shows a pharmacokinetic model in the male Yucatan, miniature swine. The study compares a 0.3 mg Epipen, a 0.12 mg Epinephrine IV and a placebo film.

Referring to **Figure 8**, this graph shows the impact of no enhancer on the concentration profiles of a 40 mg epinephrine film vs 0.3 mg Epipen.

Referring to **Figure 9**, this graph shows the impact of Enhancer A (Labrasol) on the concentration profiles of a 40 mg epinephrine film vs 0.3 mg Epipen.

Referring to **Figure 10**, this graph shows the impact of Enhancer L (clove oil) on the concentration profiles of two 40 mg Epinephrine films (10-1-1) and (11-1-1) vs. a 0.3 mg Epipen.

Referring to **Figure 11**, this graph shows the impact of Enhancer L (clove oil) and film dimension (10-1-1 thinner, bigger film and 11-1-1 thicker, smaller film) on the concentration profiles of 40 mg Epinephrine films vs. a 0.3 mg Epipen.

Referring to **Figure 12**, this graph shows the concentration profiles for varying doses of Epinephrine films in a constant matrix for Enhancer L (clove oil) vs. a 0.3 mg Epipen.

Referring to **Figure 13**, this graph shows the concentration profiles for varying doses of epinephrine films in a constant matrix for Enhancer L (clove oil) vs. a 0.3 mg Epipen.

Referring to **Figure 14**, this graph shows the concentration profiles for varying doses of epinephrine films in a constant matrix for Enhancer A (Labrasol) vs. a 0.3 mg Epipen.

Referring to **Figure 15**, this graph shows the impact of Farnesol and Farnesol in combination with Linoleic Acid on plasma concentration profiles of 40mg Epinephrine Films vs. a 0.3 mg Epipen.

Referring to **Figure 16**, this graph shows the impact of Farnesol on plasma concentration profiles of 40 mg epinephrine films vs. a 0.3 mg Epipen.

Referring to **Figure 17**, this graph shows the impact of Farnesol in combination with Linoleic Acid on plasma concentration profiles of 40 mg epinephrine films vs. a 0.3 mg Epipen.

Referring to **Figure 18**, this graph shows the impact of Farnesol and Farnesol in combination with Linoleic Acid on plasma concentration profiles of 40 mg Epinephrine Films vs. a 0.3 mg Epipen.

5 Referring to **Figure 19**, this graph shows the impact of Enhancer A (Labrasol) in combination with Enhancer L (clove oil) on the concentration profiles of a 40 mg Epinephrine film (also shown in Fig. 20), in logarithmic view.

Referring to **Figure 20**, this graph shows the impact of Enhancer A (Labrasol) in combination with Enhancer L (clove oil) on the concentration profiles of a 40 mg Epinephrine film vs. the average data collected from 0.3 mg Epipens.

10 Referring to **Figure 21**, this graph shows the impact of Enhancer A (Labrasol) in combination with Enhancer L (clove oil) on the concentration profiles of a 40 mg Epinephrine films, shown as separate animal subjects.

Referring to **Fig. 22A and Fig. 22B**, the data shows average epinephrine plasma concentration vs. time.

15 Referring to **Fig. 23A and Fig. 23B**, the data shows average dipivefrin plasma concentration vs. time.

Referring to **Fig. 24**, the data shows average plasma concentration of epinephrine administered as dipivefrin.

Referring to **Fig. 25**, the graph shows the conversion of dipivefrin to epinephrine.

20 Referring to **Fig. 26**, the data shows average average epinephrine profiles across all matrix studies.

Referring to **Fig. 27**, the data shows additional data comparing plasma concentration of dipivefrin and epinephrine.

25 Referring to **Fig. 28**, this graph shows an epinephrine concentration vs. time profile of a film treated with phentolamine.

#### DETAILED DESCRIPTION

Mucosal surfaces, such as the oral mucosa, are a convenient route for delivering drugs to the body due to the fact that they are highly vascularized and permeable, providing increased  
30 bioavailability and rapid onset of action because it does not pass through the digestive system and thereby avoids first pass metabolism. In particular, the buccal and sublingual tissues offer

advantageous sites for drug delivery because they are highly permeable regions of the oral mucosa, allowing drugs diffusing from the oral mucosa to have direct access to systemic circulation. This also offers increased convenience and therefore increased compliance in patients. For certain drugs, or pharmaceutically active components, a permeation enhancer can help to overcome the mucosal barrier and improve permeability. Permeation enhancers reversibly modulate the penetrability of the barrier layer in favor of drug absorption. Permeation enhancers facilitate transport of molecules through the epithelium. Absorption profiles and their rates can be controlled and modulated by a variety of parameters, such as but not limited to film size, drug loading, enhancer type/loading, polymer matrix release rate and mucosal residence time.

A pharmaceutical composition can be designed to deliver a pharmaceutically active component in a deliberate and tailored way. However, solubility and permeability of the pharmaceutically active component in vivo, in particular, in the mouth of a subject, can vary tremendously. A particular class of permeation enhancer can improve the uptake and bioavailability of the pharmaceutically active component in vivo. In particular, when delivered to the mouth via a film, the permeation enhancer can improve the permeability of the pharmaceutically active component through the mucosa and into the blood stream of the subject. The permeation enhancer can improve absorption rate and amount of the pharmaceutically active component by more than 5%, more than 10%, more than 20%, more than 30%, more than 40%, more than 50%, more than 60%, more than 70%, more than 80%, more than 90%, more than 100%, more than 150%, about 200% or more, or less than 200%, less than 150%, less than 100%, less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, or less than 5%, or a combination of these ranges, depending on the other components in the composition.

In certain embodiments, a pharmaceutical composition has a suitable nontoxic, nonionic alkyl glycoside having a hydrophobic alkyl group joined by a linkage to a hydrophilic saccharide in combination with a mucosal delivery-enhancing agent selected from: (a) an aggregation inhibitory agent; (b) a charge-modifying agent; (c) a pH control agent; (d) a degradative enzyme inhibitory agent; (e) a mucolytic or mucus clearing agent; (f) a ciliostatic agent; (g) a membrane penetration-enhancing agent selected from: (i) a surfactant; (ii) a bile salt; (iii) a phospholipid additive, mixed micelle, liposome, or carrier; (iv) an alcohol; (v) an enamine; (vi) an NO donor

compound; (vi) a long chain amphipathic molecule; (vii) a small hydrophobic penetration enhancer; (viii) sodium or a salicylic acid derivative; (ix) a glycerol ester of acetoacetic acid; (x) a cyclodextrin or beta-cyclodextrin derivative; (xi) a medium-chain fatty acid; (xii) a chelating agent; (xiii) an amino acid or salt thereof; (xiv) an N-acetylamino acid or salt thereof; (xv) an enzyme degradative to a selected membrane component; (ix) an inhibitor of fatty acid synthesis; (x) an inhibitor of cholesterol synthesis; and (xi) any combination of the membrane penetration enhancing agents recited in (i)-(x); (h) a modulatory agent of epithelial junction physiology; (i) a vasodilator agent; (j) a selective transport-enhancing agent; and (k) a stabilizing delivery vehicle, carrier, mucoadhesive, support or complex-forming species with which the compound is effectively combined, associated, contained, encapsulated or bound resulting in stabilization of the compound for enhanced transmucosal delivery, wherein the formulation of the compound with the transmucosal delivery-enhancing agents provides for increased bioavailability of the compound in blood plasma of a subject. Penetration enhancers have been described in J. Nicolazzo, et al., *J. of Controlled Disease*, 105 (2005) 1-15, which is incorporated by reference herein.

There are many reasons why the oral mucosa might be an attractive site for the delivery of therapeutic agents into the systemic circulation. Due to the direct drainage of blood from the buccal epithelium into the internal jugular vein first-pass metabolism in the liver and intestine may be avoided. First-pass effect can be a major reason for the poor bioavailability of some compounds when administered orally. Additionally, the mucosa lining the oral cavity is easily accessible, which ensures that a dosage form can be applied to the required site and can be removed easily in the case of an emergency. However, like the skin, the buccal mucosa acts as a barrier to the absorption of xenobiotics, which can hinder the permeation of compounds across this tissue. Consequently, the identification of safe and effective penetration enhancers has become a major goal in the quest to improve oral mucosal drug delivery.

Chemical penetration enhancers are substances that control the permeation rate of a coadministered drug through a biological membrane. While extensive research has focused on obtaining an improved understanding of how penetration enhancers might alter intestinal and transdermal permeability, far less is known about the mechanisms involved in buccal and sublingual penetration enhancement.

The buccal mucosa delineates the inside lining of the cheek as well as the area between the gums and upper and lower lips and it has an average surface area of 100 cm<sup>2</sup>. The surface of the buccal mucosa consists of a stratified squamous epithelium which is separated from the underlying connective tissue (lamina propria and submucosa) by an undulating basement  
5 membrane (a continuous layer of extracellular material approximately 1–2 µm in thickness). This stratified squamous epithelium consists of differentiating layers of cells which change in size, shape, and content as they travel from the basal region to the superficial region, where the cells are shed. There are approximately 40–50 cell layers, resulting in a buccal mucosa which is 500–600 µm thick.

10 Structurally the sublingual mucosa is comparable to the buccal mucosa but the thickness of this epithelium is 100–200 µm. This membrane is also non-keratinised and being relatively thinner has been demonstrated to be more permeable than buccal mucosa. Blood flow to the sublingual mucosal is slower compared with the buccal mucosa and is of the order of 1.0 ml/min-cm<sup>2</sup>.

15 The permeability of the buccal mucosa is greater than that of the skin, but less than that of the intestine. The differences in permeability are the result of structural differences between each of the tissues. The absence of organized lipid lamellae in the intercellular spaces of the buccal mucosa results in greater permeability of exogenous compounds, compared to keratinized epithelia of the skin; while the increased thickness and lack of tight junctions results in the  
20 buccal mucosa being less permeable than intestinal tissue.

The primary barrier properties of the buccal mucosa have been attributed to the upper one-third to one-quarter of the buccal epithelium. Researchers have learned that beyond the surface epithelium, the permeability barrier of nonkeratinized oral mucosa could also be attributed to contents extruded from the membrane-coating granules into the epithelial  
25 intercellular spaces.

The intercellular lipids of the nonkeratinized regions of the oral cavity are of a more polar nature than the lipids of the epidermis, palate, and gingiva, and this difference in the chemical nature of the lipids may contribute to the differences in permeability observed between these tissues. Consequently, it appears that it is not only the greater degree of intercellular lipid  
30 packing in the stratum corneum of keratinized epithelia that creates a more effective barrier, but also the chemical nature of the lipids present within that barrier.

The existence of hydrophilic and lipophilic regions in the oral mucosa has led researchers to postulate the existence of two routes of drug transport through the buccal mucosa paracellular (between the cells) and transcellular (across the cells).

Since drug delivery through the buccal mucosa is limited by the barrier nature of the epithelium and the area available for absorption, various enhancement strategies are required in order to deliver therapeutically relevant amounts of drug to the systemic circulation. Various methods, including the use of chemical penetration enhancers, prodrugs, and physical methods may be employed to overcome the barrier properties of the buccal mucosa.

A chemical penetration enhancer, or absorption promoter, is a substance added to a pharmaceutical formulation in order to increase the membrane permeation or absorption rate of the coadministered drug, without damaging the membrane and/or causing toxicity. There have been many studies investigating the effect of chemical penetration enhancers on the delivery of compounds across the skin, nasal mucosa, and intestine. In recent years, more attention has been given to the effect of these agents on the permeability of the buccal mucosa. Since permeability across the buccal mucosa is considered to be a passive diffusion process the steady state flux (Jss) should increase with increasing donor chamber concentration (CD) according to Fick's first law of diffusion.

Surfactants and bile salts have been shown to enhance the permeability of various compounds across the buccal mucosa, both in vitro and in vivo. The data obtained from these studies strongly suggest that the enhancement in permeability is due to an effect of the surfactants on the mucosal intercellular lipids.

Fatty acids have been shown to enhance the permeation of a number of drugs through the skin, and this has been shown by differential scanning calorimetry and Fourier transform infrared spectroscopy to be related to an increase in the fluidity of intercellular lipids.

Additionally, pretreatment with ethanol has been shown to enhance the permeability of tritiated water and albumin across ventral tongue mucosa, and to enhance caffeine permeability across porcine buccal mucosa. There are also several reports of the enhancing effect of Azone® on the permeability of compounds through oral mucosa. Further, chitosan, a biocompatible and biodegradable polymer, has been shown to enhance drug delivery through various tissues, including the intestine and nasal mucosa.

Oral transmucosal drug delivery (OTDD) is the administration of pharmaceutically active agents through the oral mucosa to achieve systemic effects. Permeation pathways and predictive models for OTDD are described, e.g. in M. Sattar, Oral transmucosal drug delivery – Current status and future prospects, *Int'l. Journal of Pharmaceutics*, 47(2014) 498-506, which is  
5 incorporated by reference herein. OTDD continues to attract the attention of academic and industrial scientists. Despite limited characterization of the permeation pathways in the oral cavity compared with skin and nasal routes of delivery, recent advances in our understanding of the extent to which ionized molecules permeate the buccal epithelium, as well as the emergence of new analytical techniques to study the oral cavity, and the progressing development of in  
10 silico models predictive of buccal and sublingual permeation, prospects are encouraging.

In order to deliver broader classes of drugs across the buccal mucosa, reversible methods of reducing the barrier potential of this tissue should be employed. This requisite has fostered the study of penetration enhancers that will safely alter the permeability restrictions of the buccal mucosa. It has been shown that buccal penetration can be improved by using various classes of  
15 transmucosal and transdermal penetration enhancers such as bile salts, surfactants, fatty acids and their derivatives, chelators, cyclodextrins and chitosan. Among these chemicals used for the drug permeation enhancement, bile salts are the most common.

In vitro studies on enhancing effect of bile salts on the buccal permeation of compounds is discussed in Sevda Senel, Drug permeation enhancement via buccal route: possibilities and limitations, *Journal of Controlled Release* 72 (2001) 133–144, which is incorporated by  
20 reference herein. That article also discusses recent studies on the effects of buccal epithelial permeability of dihydroxy bile salts, sodium glycodeoxycholate (SGDC) and sodium taurodeoxycholate (TDC) and tri-hydroxy bile salts, sodium glycocholate (GC) and sodium taurocholate (TC) at 100 mM concentration including permeability changes correlated with the  
25 histological effects. Fluorescein isothiocyanate (FITC), morphine sulfate were each used as the model compound.

Chitosan has also been shown to promote absorption of small polar molecules and peptide / protein drugs through nasal mucosa in animal models and human volunteers. Other studies have shown an enhancing effect on penetration of compounds across the intestinal  
30 mucosa and cultured Caco-2 cells.

The permeation enhancer can be a phytoextract. A phytoextract can be an essential oil or composition including essential oils extracted by distillation of the plant material. In certain circumstances, the phytoextract can include synthetic analogues of the compounds extracted from the plant material (i.e., compounds made by organic synthesis). The phytoextract can include a phenylpropanoid, for example, phenyl alanine, eugenol, eugenol acetate, a cinnamic acid, a cinnamic acid ester, a cinnamic aldehyde, a hydrocinnamic acid, chavicol, or safrole, or a combination thereof. The phytoextract can be an essential oil extract of a clove plant, for example, from the leaf, stem or flower bud of a clove plant. The clove plant can be *Syzygium aromaticum*. The phytoextract can include 20-95% eugenol, including 40-95% eugenol, including 60-95% eugenol, and for example, 80-95% eugenol. The extract can also include 5% to 15% eugenol acetate. The extract can also include caryophyllene. The extract can also include up to 2.1%  $\alpha$ -humulene. Other volatile compounds included in lower concentrations in clove essential oil can be  $\beta$ -pinene, limonene, farnesol, benzaldehyde, 2-heptanone and ethyl hexanoate. Other permeation enhancers may be added to the composition to improve absorption of the drug. Suitable permeation enhancers include natural or synthetic bile salts such as sodium fusidate; glycocholate or deoxycholate and their salts; fatty acids and derivatives such as sodium laurate, oleic acid, oleyl alcohol, monoolein, and palmitoylcarnitine; chelators such as disodium EDTA, sodium citrate and sodium laurylsulfate, azone, sodium cholate, sodium 5-methoxysalicylate, sorbitan laurate, glyceryl monolaurate, octoxynonyl-9, laureth-9, polysorbates, sterols, or glycerides, such as caprylocaproyl polyoxylglycerides, e.g., Labrasol. The permeation enhancer can include phytoextract derivatives and/or monolignols. The permeation enhancer can also be a fungal extract.

Some natural products of plant origin have been known to have a vasodilatory effect. There are several mechanisms or modes by which plant-based products can evoke vasodilation. For review, see McNeill J.R. and Jurgens, T.M., *Can. J. Physiol. Pharmacol.* 84:803-821 (2006), which is incorporated by reference herein. Specifically, vasorelaxant effects of eugenol have been reported in a number of animal studies. See, e.g., Lahlou, S., et al., *J. Cardiovasc. Pharmacol.* 43:250-57 (2004), Damiani, C.E.N., et al., *Vascular Pharmacol.* 40:59-66 (2003), Nishijima, H., et al., *Japanese J. Pharmacol.* 79:327-334 (1998), and Hume W.R., *J. Dent Res.* 62(9):1013-15 (1983), each of which is incorporated by reference herein. Calcium channel blockade was suggested to be responsible for vascular relaxation induced by a plant essential oil,



or its main constituent, eugenol. See, Interaminense L.R.L. et al., Fundamental & Clin. Pharmacol. 21: 497-506 (2007), which is incorporated by reference herein.

Fatty acids can be used as inactive ingredients in drug preparations or drug vehicles. Fatty acids can also be used as formulation ingredients due to their certain functional effects and their biocompatible nature. Fatty acid, both free and as part of complex lipids, are major metabolic fuel (storage and transport energy), essential components of all membranes and gene regulators. For review, see Rustan A.C. and Drevon, C.A., Fatty Acids: Structures and Properties, Encyclopedia of Life Sciences (2005), which is incorporated by reference herein.

There are two families of essential fatty acids that are metabolized in the human body:  $\omega$ -3 and  $\omega$ -6 polyunsaturated fatty acids (PUFAs). If the first double bond is found between the third and the fourth carbon atom from the  $\omega$  carbon, they are called  $\omega$ -3 fatty acids. If the first double bond is between the sixth and seventh carbon atom, they are called  $\omega$ -6 fatty acids. PUFAs are further metabolized in the body by the addition of carbon atoms and by desaturation (extraction of hydrogen). Linoleic acid, which is a  $\omega$ -6 fatty acid, is metabolized to  $\gamma$ -linolenic acid, dihomo- $\gamma$ -linolenic acid, arachidonic acid, adrenic acid, tetracosatetraenoic acid, tetracosapentaenoic acid and docosapentaenoic acid.  $\alpha$ -linolenic acid, which is a  $\omega$ -3 fatty acid is metabolized to octadecatetraenoic acid, eicosatetraenoic acid, eicosapentaenoic acid (EPA), docosapentaenoic acid, tetracosapentaenoic acid, tetracosahexaenoic acid and docosahexaenoic acid (DHA).

It has been reported that fatty acids, such as palmitic acid, oleic acid, linoleic acid and eicosapentaenoic acid, induced relaxation and hyperpolarization of porcine coronary artery smooth muscle cells via a mechanism involving activation of the  $\text{Na}^+\text{K}^+$ -ATPase pump and the fatty acids with increasing degrees of *cis*-unsaturation had higher potencies. See, Pomposiello, S.I. et al., Hypertension 31:615-20 (1998), which is incorporated by reference herein.

Interestingly, the pulmonary vascular response to arachidonic acid, a metabolite of linoleic acid, can be either vasoconstrictive or vasodilative, depending on the dose, animal species, the mode of arachidonic acid administration, and the tones of the pulmonary circulation. For example, arachidonic acid has been reported to cause cyclooxygenase-dependent and -independent pulmonary vasodilation. See, Feddersen, C.O. et al., J. Appl. Physiol. 68(5):1799-808 (1990); and see, Spannhake, E.W., et al., J. Appl. Physiol. 44:397-495 (1978) and Wicks, T.C. et al., Circ. Res. 38:167-71 (1976), each of which is incorporated by reference herein.

Many studies have reported effects of EPA and DHA on vascular reactivity after being administered as ingestible forms. Some studies found that EPA-DHA or EPA alone suppressed the vasoconstrictive effect of norepinephrine or increased vasodilatory responses to acetylcholine in the forearm microcirculation. See, Chin, J.P.F, et al., Hypertension 21:22-8 (1993), and  
5 Tagawa, H. et al., J Cardiovasc Pharmacol 33:633-40 (1999), each of which is incorporated by reference herein. Another study found that both EPA and DHA increased systemic arterial compliance and tended to reduce pulse pressure and total vascular resistance. See, Nestel, P. et al., Am J. Clin. Nutr. 76:326-30 (2002), which is incorporated by reference herein. Meanwhile, a study found that DHA, but not EPA, enhanced vasodilator mechanisms and attenuates constrictor  
10 responses in forearm microcirculation in hyperlipidemic overweight men. See, Mori, T.A., et al., Circulation 102:1264-69 (2000), which is incorporated by reference herein. Another study found vasodilator effects of DHA on the rhythmic contractions of isolated human coronary arteries *in vitro*. See Wu, K.-T. et al., Chinese J. Physiol. 50(4):164-70 (2007), which is incorporated by reference herein.

15 The adrenergic receptors (or adrenoceptors) are a class of G protein-coupled receptors that are a target of catecholamines, especially norepinephrine (noradrenaline) and epinephrine (adrenaline). Epinephrine (adrenaline) interacts with both  $\alpha$ - and  $\beta$ -adrenoceptors, causing vasoconstriction and vasodilation, respectively. Although  $\alpha$  receptors are less sensitive to epinephrine, when activated, they override the vasodilation mediated by  $\beta$ -adrenoceptors because  
20 there are more peripheral  $\alpha_1$  receptors than  $\beta$ -adrenoceptors. The result is that high levels of circulating epinephrine cause vasoconstriction. At lower levels of circulating epinephrine,  $\beta$ -adrenoceptor stimulation dominates, producing vasodilation followed by decrease of peripheral vascular resistance. The  $\alpha_1$ -adrenoreceptor is known for smooth muscle contraction, mydriasis, vasoconstriction in the skin, mucosa and abdominal viscera and sphincter contraction of the  
25 gastrointestinal (GI) tract and urinary bladder. The  $\alpha_1$ -adrenergic receptors are member of the  $G_q$  protein-coupled receptor superfamily. Upon activation, a heterotrimeric G protein,  $G_q$ , activates phospholipase C (PLC). The mechanism of action involves interaction with calcium channels and changing the calcium content in a cell. For review, see Smith R. S. et al., Journal of Neurophysiology 102(2): 1103-14 (2009), which is incorporated by reference herein. Many cells  
30 possess these receptors.

$\alpha$ 1-adrenergic receptors can be a main receptor for fatty acids. For example, saw palmetto extract (SPE), widely used for the treatment of benign prostatic hyperplasia (BPH), has been reported to bind  $\alpha$ 1-adrenergic, muscarinic and 1,4-dihydropyridine (1,4-DHP) calcium channel antagonist receptors. See, Abe M., et al., Biol. Pharm. Bull. 32(4) 646-650 (2009), and Suzuki M. et al., Acta Pharmacologica Sinica 30:271-81 (2009), each of which is incorporated by reference herein. SPE includes a variety of fatty acids including lauric acid, oleic acid, myristic acid, palmitic acid and linoleic acid. Lauric acid and oleic acid can bind noncompetitively to  $\alpha$ 1-adrenergic, muscarinic and 1,4-DHP calcium channel antagonist receptors.

In certain embodiments, a permeation enhancer can be an adrenergic receptor interacter.

An adrenergic receptor interacter refers to a compound or substance that modifies and/or otherwise alters the action of an adrenergic receptor. For example, an adrenergic receptor interacter can prevent stimulation of the receptor by increasing, or decreasing their ability to bind. Such interacters can be provided in either short-acting or long-acting forms. Certain short-acting interacters can work quickly, but their effects last only a few hours. Certain long-acting interacters can take longer to work, but their effects can last longer. The interacter can be selected and/or designed based on, e.g., on one or more of the desired delivery and dose, active pharmaceutical ingredient, permeation modifier, permeation enhancer, matrix, and the condition being treated. An adrenergic receptor interacter can be an adrenergic receptor blocker. The adrenergic receptor interacter can be a terpene (e.g. volatile unsaturated hydrocarbons found in the essential oils of plants, derived from units of isoprenes) or a C3-C22 alcohol or acid, preferably a C7-C18 alcohol or acid. In certain embodiments, the adrenergic receptor interacter can include farnesol, linoleic acid, arachidonic acid, docosahexanoic acid, eicosapentanoic acid, and/or docosapentanoic acid. The acid can be a carboxylic acid, phosphoric acid, sulfuric acid, hydroxamic acid, or derivatives thereof. The derivative can be an ester or amide. For example, the adrenergic receptor interacter can be a fatty acid or fatty alcohol.

The C3-C22 alcohol or acid can be an alcohol or acid having a straight C3-C22 hydrocarbon chain, for example a C3-C22 hydrocarbon chain optionally containing at least one double bond, at least one triple bond, or at least one double bond and one triple bond; said hydrocarbon chain being optionally substituted with C<sub>1-4</sub> alkyl, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, C<sub>1-4</sub> alkoxy, hydroxyl, halo, amino, nitro, cyano, C<sub>3-5</sub> cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl, C<sub>1-4</sub> alkylcarbonyloxy, C<sub>1-4</sub> alkylloxycarbonyl, C<sub>1-4</sub>

alkylcarbonyl, or formyl; and further being optionally interrupted by -O-, -N(R<sup>a</sup>)-, -N(R<sup>a</sup>)-C(O)-O-, -O-C(O)-N(R<sup>a</sup>)-, -N(R<sup>a</sup>)-C(O)-N(R<sup>b</sup>)-, or -O-C(O)-O-. Each of R<sup>a</sup> and R<sup>b</sup>, independently, is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl.

Fatty acids with a higher degree of unsaturation are effective candidates to enhance the permeation of drugs. Unsaturated fatty acids showed higher enhancement than saturated fatty acids, and the enhancement increased with the number of double bonds. See, A. Mittal, et al. Status of Fatty Acids as Skin Penetration Enhancers – A Review, *Current Drug Delivery*, 2009, 6, pp. 274-279, which is incorporated by reference herein. Position of double bond also affects the enhancing activity of fatty acids. Differences in the physicochemical properties of fatty acid which originate from differences in the double bond position most likely determine the efficacy of these compounds as skin penetration enhancers. Skin distribution increases as the position of the double bond is shifted towards the hydrophilic end. It has also been reported that fatty acid which has a double bond at an even number position more rapidly effects the perturbation of the structure of both the stratum corneum and the dermis than a fatty acid which has double bond at an odd number position. Cis-unsaturation in the chain can tend to increase activity.

An adrenergic receptor interacter can be a terpene. Hypotensive activity of terpenes in essential oils has been reported. See, Menezes I.A. et al., *Z. Naturforsch.* 65c:652-66 (2010), which is incorporated by reference herein. In certain embodiments, the permeation enhancer can be a sesquiterpene. Sesquiterpenes are a class of terpenes that consist of three isoprene units and have the empirical formula C<sub>15</sub>H<sub>24</sub>. Like monoterpenes, sesquiterpenes may be acyclic or contain rings, including many unique combinations. Biochemical modifications such as oxidation or rearrangement produce the related sesquiterpenoids.

An adrenergic receptor interacter can be an unsaturated fatty acid such as linoleic acid. In certain embodiments, the permeation enhancer can be farnesol. Farnesol is a 15-carbon organic compound which is an acyclic sesquiterpene alcohol, which is a natural dephosphorylated form of farnesyl pyrophosphate. Under standard conditions, it is a colorless liquid. It is hydrophobic, and thus insoluble in water, but miscible with oils. Farnesol can be extracted from oils of plants such as citronella, neroli, cyclamen, and tuberose. It is an intermediate step in the biological synthesis of cholesterol from mevalonic acid in vertebrates. It has a delicate floral or weak citrus-lime odor and is used in perfumes and flavors. It has been reported that farnesol selectively kills acute myeloid leukemia blasts and leukemic cell lines in

preference to primary hemopoietic cells. See, Rioja A. et al., FEBS Lett 467 (2-3): 291-5 (2000), which is incorporated by reference herein. Vasoactive properties of farnesyl analogues have been reported. See, Roullet, J.-B., et al., J. Clin. Invest., 1996, 97:2384-2390, which is incorporated by reference herein. Both Farnesol and N-acetyl-S-trans, trans-farnesyl-L-cysteine (AFC), a  
5 synthetic mimic of the carboxyl terminus of farnesylated proteins inhibited vasoconstriction in rat aortic rings.

In certain embodiments, an interacter can be an aporphine alkaloid. For example, an interacter can be a dicentrine.

In general, an interacter can also be a vasodilator or a therapeutic vasodilator.

10 Vasodilators are drugs that open or widen blood vessels. They are typically used to treat hypertension, heart failure and angina, but can be used to treat other conditions as well, including glaucoma for example. Some vasodilators that act primarily on resistance vessels (arterial dilators) are used for hypertension, and heart failure, and angina; however, reflex cardiac stimulation makes some arterial dilators unsuitable for angina. Venous dilators are very effective  
15 for angina, and sometimes used for heart failure, but are not used as primary therapy for hypertension. Vasodilator drugs can be mixed (or balanced) vasodilators in that they dilate both arteries and veins and therefore can have wide application in hypertension, heart failure and angina. Some vasodilators, because of their mechanism of action, also have other important actions that can in some cases enhance their therapeutic utility or provide some additional  
20 therapeutic benefit. For example, some calcium channel blockers not only dilate blood vessels, but also depress cardiac mechanical and electrical function, which can enhance their antihypertensive actions and confer additional therapeutic benefit such as blocking arrhythmias.

Vasodilator drugs can be classified based on their site of action (arterial versus venous) or by mechanism of action. Some drugs primarily dilate resistance vessels (arterial dilators; e.g.,  
25 hydralazine), while others primarily affect venous capacitance vessels (venous dilators; e.g., nitroglycerine). Many vasodilator drugs have mixed arterial and venous dilator properties (mixed dilators; e.g., alpha-adrenoceptor antagonists, angiotensin converting enzyme inhibitors), such as phentolamine.

It is more common, however, to classify vasodilator drugs based on their primary  
30 mechanism of action. The figure to the right depicts important mechanistic classes of vasodilator drugs. These classes of drugs, as well as other classes that produce vasodilation, include: alpha-

adrenoceptor antagonists (alpha-blockers); Angiotensin converting enzyme (ACE) inhibitors; Angiotensin receptor blockers (ARBs); beta<sub>2</sub>-adrenoceptor agonists (β<sub>2</sub>-agonists); calcium-channel blockers (CCBs); centrally acting sympatholytics; direct acting vasodilators; endothelin receptor antagonists; ganglionic blockers; nitrodilators; phosphodiesterase inhibitors; potassium-channel openers; renin inhibitors.

In general, the active or inactive components or ingredients can be substances or compounds that create an increased blood flow or flushing of the tissue to enable a modification or difference (increase or decrease) in transmucosal uptake of the API(s), and/or have a positive or negative heat of solution which are used as aids to modify (increase or decrease) transmucosal uptake.

#### **Sequence of Permeation Enhancer(s) and Active Pharmaceutical Ingredient(s)**

The arrangement, order, or sequence of penetration enhancer(s) and active pharmaceutical ingredient(s)(API(s)) delivered to the desired mucosal surface can vary in order to deliver a desired pharmacokinetic profile. For example, one can apply the permeation enhancer(s) first by a film, by swab, spray, gel, rinse or by a first layer of a film then apply the API(s) by single film, by swab, or by a second layer of a film. The sequence can be reversed or modified, for example, by applying the API(s) first by film, by swab, or by a first layer of a film, and then applying the permeation enhancer(s) by a film, by swab, spray, gel, rinse or by a second layer of a film. In another embodiment, one may apply a permeation enhancer(s) by a film, and a drug by a different film. For example, the permeation enhancer(s) film positioned under a film containing the API(s), or the film containing the API(s) positioned under a film containing the permeation enhancer(s), depending on the desired pharmacokinetic profile.

For example, the penetration enhancer(s) can be used as a pretreatment alone or in combination with at least one API to precondition the mucosa for further absorption of the API(s). The treatment can be followed by another treatment with neat penetration enhancer(s) to follow the at least one API mucosal application. The pretreatment can be applied as a separate treatment (film, gel, solution, swab etc.) or as a layer within a multilayered film construction of one or more layers. Similarly, the pretreatment may be contained within a distinct domain of a single film, designed to dissolve and release to the mucosa prior to release of the secondary domains with or without penetration enhancer(s) or API(s). The active ingredient may then be delivered from a second treatment, alone or in combination with additional penetration

enhancer(s). There may also be a tertiary treatment or domain that delivers additional penetration enhancer(s) and/or at least one API(s) or prodrug(s), either at a different ratio relative to each other or relative to the overall loading of the other treatments. This allows a custom pharmacokinetic profile to be obtained. In this way, the product may have single or multiple domains, with penetration enhancer(s) and API(s) that can vary in mucosal application order, composition, concentration, or overall loading that leads to the desired absorption amounts and/or rates that achieve the intended pharmacokinetic profile and/or pharmacodynamic effect.

The film format can be oriented such that no distinct sides, or such that the film has at least one side of a multiple layer film where the edges are co-terminus (having or meeting at a shared border or limit).

The pharmaceutical composition can be a chewable or gelatin based dosage form, spray, gum, gel, cream, tablet, liquid or film. The composition can include textures, for example, at the surface, such as microneedles or micro-protrusions. Recently, the use of micron-scale needles in increasing skin permeability has been shown to significantly increase transdermal delivery, including and especially for macromolecules. Most drug delivery studies have emphasized solid microneedles, which have been shown to increase skin permeability to a broad range of molecules and nanoparticles in vitro. In vivo studies have demonstrated delivery of oligonucleotides, reduction of blood glucose level by insulin, and induction of immune responses from protein and DNA vaccines. For such studies, needle arrays have been used to pierce holes into skin to increase transport by diffusion or iontophoresis or as drug carriers that release drug into the skin from a microneedle surface coating. Hollow microneedles have also been developed and shown to microinject insulin to diabetic rats. To address practical applications of microneedles, the ratio of microneedle fracture force to skin insertion force (i.e. margin of safety) was found to be optimal for needles with small tip radius and large wall thickness. Microneedles inserted into the skin of human subjects were reported as painless. Together, these results suggest that microneedles represent a promising technology to deliver therapeutic compounds into the skin for a range of possible applications. Using the tools of the microelectronics industry, microneedles have been fabricated with a range of sizes, shapes and materials. Microneedles can be, for example, polymeric, microscopic needles that deliver encapsulated drugs in a minimally invasive manner, but other suitable materials can be used.

Applicants have found that microneedles could be used to enhance the delivery of drugs through the oral mucosa, particularly with the claimed compositions. The microneedles create micron sized pores in the oral mucosa which can enhance the delivery of drugs across the mucosa. Solid, hollow or dissolving microneedles can be fabricated out of suitable materials including, but not limited to, metal, polymer, glass and ceramics. The microfabrication process can include photolithography, silicon etching, laser cutting, metal electroplating, metal electro polishing and molding. Microneedles could be solid which is used to pretreat the tissue and are removed before applying the film. The drug loaded polymer film described in this application can be used as the matrix material of the microneedles itself. These films can have microneedles or micro protrusions fabricated on their surface which will dissolve after forming microchannels in the mucosa through which drugs can permeate.

The term "film" can include films and sheets, in any shape, including rectangular, square, or other desired shape. A film can be any desired thickness and size. In preferred embodiments, a film can have a thickness and size such that it can be administered to a user, for example, placed into the oral cavity of the user. A film can have a relatively thin thickness of from about 0.0025mm to about 0.250mm, or a film can have a somewhat thicker thickness of from about 0.250mm to about 1.0mm. For some films, the thickness may be even larger, i.e., greater than about 1.0mm or thinner, i.e., less than about 0.0025mm. A film can be a single layer or a film can be multi-layered, including laminated or multiple cast films. A permeation enhancer and pharmaceutically active component can be combined in a single layer, each contained in separate layers, or can each be otherwise contained in discrete regions of the same dosage form. In certain embodiments, the pharmaceutically active component contained in the polymeric matrix can be dispersed in the matrix. In certain embodiments, the permeation enhancer being contained in the polymeric matrix can be dispersed in the matrix.

Oral dissolving films can fall into three main classes: fast dissolving, moderate dissolving and slow dissolving. Oral dissolving films can also include a combination of any of the above categories. Fast dissolving films can dissolve in about 1 second to about 30 seconds in the mouth, including more than 1 second, more than 5 seconds, more than 10 seconds, more than 20 seconds, and less than 30 seconds. Moderate dissolving films can dissolve in about 1 to about 30 minutes in the mouth including more than 1 minute, more than 5 minutes, more than 10 minutes, more than 20 minutes or less than 30 minutes, and slow dissolving films can dissolve in more



than 30 minutes in the mouth. As a general trend, fast dissolving films can include (or consist of) low molecular weight hydrophilic polymers (e.g., polymers having a molecular weight between about 1,000 to 9,000 daltons, or polymers having a molecular weight up to 200,000 daltons). In contrast, slow dissolving films generally include high molecular weight polymers (e.g., having a molecular weight in millions). Moderate dissolving films can tend to fall in between the fast and slow dissolving films.

It can be preferable to use films that are moderate dissolving films. Moderate dissolving films can dissolve rather quickly, but also have a good level of mucoadhesion. Moderate dissolving films can also be flexible, quickly wettable, and are typically non-irritating to the user. Such moderate dissolving films can provide a quick enough dissolution rate, most desirably between about 1 minute and about 20 minutes, while providing an acceptable mucoadhesion level such that the film is not easily removable once it is placed in the oral cavity of the user. This can ensure delivery of a pharmaceutically active component to a user.

A pharmaceutical composition can include one or more pharmaceutically active components. The pharmaceutically active component can be a single pharmaceutical component or a combination of pharmaceutical components. The pharmaceutically active component can be an anti-inflammatory analgesic agent, a steroidal anti-inflammatory agent, an antihistamine, a local anesthetic, a bactericide, a disinfectant, a vasoconstrictor, a hemostatic, a chemotherapeutic drug, an antibiotic, a keratolytic, a cauterizing agent, an antiviral drug, an antirheumatic, an antihypertensive, a bronchodilator, an anticholinergic, an anti-anxiety drug, an antiemetic compound, a hormone, a peptide, a protein or a vaccine. The pharmaceutically active component can be the compound, pharmaceutically acceptable salt of a drug, a prodrug, a derivative, a drug complex or analog of a drug. The term "prodrug" refers to a biologically inactive compound that can be metabolized in the body to produce a biologically active drug. For example, the pharmaceutically active component can be an ester of epinephrine, for example, dipivefrin. *See, e.g., J. Anderson, et al., Site of ocular hydrolysis of a prodrug, dipivefrin, and a comparison of its ocular metabolism with that of the parent compounds, epinephrine, Invest., Ophthalmol. Vis. Sci. July 1980.*

In some embodiments, more than one pharmaceutically active component may be included in the film. The pharmaceutically active components can be ace-inhibitors, anti-anginal drugs, anti-arrhythmias, anti-asthmatics, anti-cholesterolemics, analgesics, anesthetics, anti-

convulsants, anti-depressants, anti-diabetic agents, anti-diarrhea preparations, antidotes, anti-histamines, anti-hypertensive drugs, anti-inflammatory agents, anti-lipid agents, anti-manics, anti-nauseants, anti-stroke agents, anti-thyroid preparations, amphetamines, anti-tumor drugs, anti-viral agents, acne drugs, alkaloids, amino acid preparations, anti-tussives, anti-uricemic  
5 drugs, anti-viral drugs, anabolic preparations, systemic and non-systemic anti-infective agents, anti-neoplastics, anti-parkinsonian agents, anti-rheumatic agents, appetite stimulants, blood modifiers, bone metabolism regulators, cardiovascular agents, central nervous system stimulates, cholinesterase inhibitors, contraceptives, decongestants, dietary supplements, dopamine receptor agonists, endometriosis management agents, enzymes, erectile dysfunction therapies, fertility  
10 agents, gastrointestinal agents, homeopathic remedies, hormones, hypercalcemia and hypocalcemia management agents, immunomodulators, immunosuppressives, migraine preparations, motion sickness treatments, muscle relaxants, obesity management agents, osteoporosis preparations, oxytocics, parasympatholytics, parasympathomimetics, prostaglandins, psychotherapeutic agents, respiratory agents, sedatives, smoking cessation aids,  
15 sympatholytics, tremor preparations, urinary tract agents, vasodilators, laxatives, antacids, ion exchange resins, anti-pyretics, appetite suppressants, expectorants, anti-anxiety agents, anti-ulcer agents, anti-inflammatory substances, coronary dilators, cerebral dilators, peripheral vasodilators, psycho-tropics, stimulants, anti-hypertensive drugs, vasoconstrictors, migraine treatments, antibiotics, tranquilizers, anti-psychotics, anti-tumor drugs, anti-coagulants, anti-  
20 thrombotic drugs, hypnotics, anti-emetics, anti-nauseants, anti-convulsants, neuromuscular drugs, hyper- and hypo-glycemic agents, thyroid and anti-thyroid preparations, diuretics, anti-spasmodics, uterine relaxants, anti-obesity drugs, erythropoietic drugs, anti-asthmatics, cough suppressants, mucolytics, DNA and genetic modifying drugs, diagnostic agents, imaging agents, dyes, or tracers, and combinations thereof.

25 For example, the pharmaceutically active component can be buprenorphine, naloxone, acetaminophen, riluzole, clobazam, Rizatriptan, propofol, methyl salicylate, monoglycol salicylate, aspirin, mefenamic acid, flufenamic acid, indomethacin, diclofenac, alclofenac, diclofenac sodium, ibuprofen, ketoprofen, naproxen, pranoprofen, fenoprofen, sulindac, fenclofenac, clidanac, flurbiprofen, fentiazac, bufexamac, piroxicam, phenylbutazone,  
30 oxyphenbutazone, clofezone, pentazocine, mepirizole, tiaramide hydrochloride, hydrocortisone, predonisolone, dexarnethasone, triamcinolone acetonide, fluocinolone acetonide, hydrocortisone

acetate, predonisolone acetate, methylpredonisolone, dexamethasone acetate, betamethasone, betamethasone valerate, flumetasone, fluorometholone, beclomethasone dipropionate, fluocinonide, edaravone, lurasidone, esomeprazole, lumateperone, naldmedine, doxylamine, pyridoxine, diphenhydramine hydrochloride, diphenhydramine salicylate, diphenhydramine, 5 chlorpheniramine hydrochloride, chlorpheniramine maleate isothipendyl hydrochloride, tripeleminamine hydrochloride, promethazine hydrochloride, methdilazine hydrochloride dibucaine hydrochloride, dibucaine, lidocaine hydrochloride, lidocaine, benzocaine, p-buthylaminobenzoic acid 2-(diethylamino) ethyl ester hydrochloride, procaine hydrochloride, tetracaine, tetracaine hydrochloride, chlorprocaine hydrochloride, oxyprocaine hydrochloride, 10 mepivacaine, cocaine hydrochloride, piperocaine hydrochloride, dyclonine, dyclonine hydrochloride, thimerosal, phenol, thymol, benzalkonium chloride, benzethonium chloride, chlorhexidine, povidone iodide, cetylpyridinium chloride, eugenol, trimethylammonium bromide, naphazoline nitrate, tetrahydrozoline hydrochloride, oxymetazoline hydrochloride, phenylephrine hydrochloride, tramazoline hydrochloride, thrombin, phytonadione, protamine 15 sulfate, aminocaproic acid, tranexamic acid, carbazochrome, carbaxochrome sodium sulfanate, rutin, hesperidin, sulfamine, sulfathiazole, sulfadiazine, homosulfamine, sulfisoxazole, sulfisomidine, sulfamethizole, nitrofurazone, penicillin, meticillin, oxacillin, cefalotin, cefalordin, erythromycin, lincomycin, tetracycline, chlortetracycline, oxytetracycline, metacycline, chloramphenicol, kanamycin, streptomycin, gentamicin, bacitracin, cycloserine, 20 salicylic acid, podophyllum resin, podolifox, cantharidin, chloroacetic acids, silver nitrate, protease inhibitors, thymidine kinase inhibitors, sugar or glycoprotein synthesis inhibitors, structural protein synthesis inhibitors, attachment and adsorption inhibitors, and nucleoside analogues such as acyclovir, penciclovir, valacyclovir, and ganciclovir, heparin, insulin, LHRH, TRH, interferons, oligonucleotides, calcitonin, octreotide, omeprazole, fluoxetine, ethinylestradiol, 25 amiodipine, paroxetine, enalapril, lisinopril, leuprolide, prevastatin, lovastatin, norethindrone, risperidone, olanzapine, albuterol, hydrochlorothiazide, pseudoephedrine, warfarin, terazosin, cisapride, ipratropium, buspirone, methylphenidate, levothyroxine, zolpidem, levonorgestrel, glyburide, benazepril, medroxyprogesterone, clonazepam, ondansetron, losartan, quinapril, nitroglycerin, midazolam versed, cetirizine, doxazosin, glipizide, vaccine hepatitis B, salmeterol, 30 sumatriptan, triamcinolone acetonide, goserelin, beclomethasone, granisteron, desogestrel, alprazolam, estradiol, nicotine, interferon beta 1A, cromolyn, fosinopril, digoxin, fluticasone,

bisoprolol, calcitriol, captopril, butorphanol, clonidine, premarin, testosterone, sumatriptan, clotrimazole, bisacodyl, dextromethorphan, nitroglycerine, nafarelin, dinoprostone, nicotine, bisacodyl, goserelin, and granisetron. In certain embodiments, the pharmaceutically active component can be epinephrine, a prodrug of epinephrine a benzodiazepine such as diazepam or lorazepam or alprazolam.

#### Epinephrine/Dipivefrin Examples


In one example, a composition including epinephrine or its salts or esters (such as dipivefrin) can have a biodelivery profile similar to that of epinephrine administered by injection, for example, using an EpiPen. Epinephrine or its prodrug can be present in an amount of from about .01 mg to about 100 mg per dosage, for example, at a 0.1 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg or 100 mg dosage, including greater than 0.1 mg, more than 5 mg, more than 20 mg, more than 30 mg, more than 40 mg, more than 50 mg, more than 60 mg, more than 70 mg, more than 80 mg, more than 90 mg, or less than 100 mg, less than 90 mg, less than 80 mg, less than 70 mg, less than 60 mg, less than 50 mg, less than 40 mg, less than 30 mg, less than 20 mg, less than 10 mg, or less than 5 mg, or any combination thereof. In another example, a composition including diazepam can have a biodelivery profile similar to that of a diazepam tablet or gel, or better.

Dipivefrin can be present in an amount of from about 0.5 mg to about 100 mg per dosage, for example, at a 0.5mg, 1 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg or 100 mg dosage including greater than 1 mg, more than 5 mg, more than 20 mg, more than 30 mg, more than 40 mg, more than 50 mg, more than 60 mg, more than 70 mg, more than 80 mg, more than 90 mg, or less than 100 mg, less than 90 mg, less than 80 mg, less than 70 mg, less than 60 mg, less than 50 mg, less than 40 mg, less than 30 mg, less than 20 mg, less than 10 mg, or less than 5 mg, or any combination thereof.

In another example, a composition (e.g., including epinephrine) can have a suitable nontoxic, nonionic alkyl glycoside having a hydrophobic alkyl group joined by a linkage to a hydrophilic saccharide in combination with a mucosal delivery-enhancing agent selected from: (a) an aggregation inhibitory agent; (b) a charge-modifying agent; (c) a pH control agent; (d) a degradative enzyme inhibitory agent; (e) a mucolytic or mucus clearing agent; (f) a ciliostatic agent; (g) a membrane penetration-enhancing agent selected from: (i) a surfactant; (ii) a bile salt;

(ii) a phospholipid additive, mixed micelle, liposome, or carrier; (iii) an alcohol; (iv) an enamine; (v) an NO donor compound; (vi) a long chain amphipathic molecule; (vii) a hydrophobic penetration enhancer; (viii) sodium or a salicylic acid derivative; (ix) a glycerol ester of acetoacetic acid; (x) a cyclodextrin or beta-cyclodextrin derivative; (xi) a medium-chain fatty acid; (xii) a chelating agent; (xiii) an amino acid or salt thereof; (xiv) an N-acetylamino acid or salt thereof; (xv) an enzyme degradative to a selected membrane component; (ix) an inhibitor of fatty acid synthesis; (x) an inhibitor of cholesterol synthesis; and (xi) any combination of the membrane penetration enhancing agents recited in (i)-(x); (h) a modulatory agent of epithelial junction physiology; (i) a vasodilator agent; (j) a selective transport-enhancing agent; or (k) a stabilizing delivery vehicle, carrier, mucoadhesive, support or complex-forming species with which the compound is effectively combined, associated, contained, encapsulated or bound resulting in stabilization of the compound for enhanced mucosal delivery, wherein the formulation of the compound with the transmucosal delivery-enhancing agents provides for increased bioavailability of the compound in a blood plasma of a subject. The formulation can include approximately the same active pharmaceutical ingredient (API): enhancer ratio as in the other examples for epinephrine.

Administering epinephrine as a prodrug such as dipivefrin confers certain advantages. For one, dipivefrin is lipophilic and therefore has a higher permeation through a mucosa. It also has a longer plasma half life due to higher protein binding. It is capable of sustained blood levels, and does not interact with  $\alpha$ -receptors, therefore minimizing or eliminating unwanted or harmful vasoconstriction.



Dipifeverin can be provided as sublingual film in a similar manner as with epinephrine.

A film and/or its components can be water-soluble, water swellable or water-insoluble.

The term “water-soluble” can refer to substances that are at least partially dissolvable in an aqueous solvent, including but not limited to water. The term “water-soluble” may not necessarily mean that the substance is 100% dissolvable in the aqueous solvent. The term “water-insoluble” refers to substances that are not dissolvable in an aqueous solvent, including but not limited to water. A solvent can include water, or alternatively can include other solvents (preferably, polar solvents) by themselves or in combination with water.

The composition can include a polymeric matrix. Any desired polymeric matrix may be used, provided that it is orally dissolvable or erodible. The dosage should have enough bioadhesion to not be easily removed and it should form a gel like structure when administered. They can be moderate-dissolving in the oral cavity and particularly suitable for delivery of pharmaceutically active components, although both fast release, delayed release, controlled release and sustained release compositions are also among the various embodiments contemplated.

#### Branched Polymers

The pharmaceutical composition film can include dendritic polymers which can include highly branched macromolecules with various structural architectures. The dendritic polymers can include dendrimers, dendronised polymers (dendrigrafted polymers), linear dendritic hybrids, multi-arm star polymers, or hyperbranched polymers.

Hyperbranched polymers are highly branched polymers with imperfections in their structure. However they can be synthesized in a single step reaction which can be an advantage over other dendritic structures and are therefore suitable for bulk volume applications. The properties of these polymers apart from their globular structure are the abundant functional groups, intramolecular cavities, low viscosity and high solubility. Dendritic polymers have been used in several drug delivery applications. See, e.g., Dendrimers as Drug Carriers: Applications in Different Routes of Drug Administration. J Pharm Sci, VOL. 97, 2008, 123-143, which is incorporated by reference herein.

The dendritic polymers can have internal cavities which can encapsulate drugs. The steric hindrance caused by the highly dense polymer chains might prevent the crystallization of the

drugs. Thus, branched polymers can provide additional advantages in formulating crystallizable drugs in a polymer matrix.

Examples of suitable dendritic polymers include poly(ether) based dendrons, dendrimers and hyperbranched polymers, poly(ester) based dendrons, dendrimers and hyperbranched  
5 polymers, poly(thioether) based dendrons, dendrimers and hyperbranched polymers, poly(amino acid) based dendrons dendrimers and hyperbranched polymers, poly(arylalkylene ether) based dendrons, dendrimers and hyperbranched polymers, poly(alkyleneimine) based dendrons, dendrimers and hyperbranched polymers, poly(amidoamine) based dendrons, dendrimers or hyperbranched polymers.

10 Other examples of hyperbranched polymers include poly(amines)s, polycarbonates, poly(ether ketone)s, polyurethanes, polycarbosilanes, polysiloxanes, poly(ester amine)s, poly(sulfone amine)s, poly(urea urethane)s and polyether polyols such as polyglycerols.

A film can be produced by a combination of at least one polymer and a solvent, optionally including other components. The solvent may be water, a polar organic solvent  
15 including, but not limited to, ethanol, isopropanol, acetone, or any combination thereof. In some embodiments, the solvent may be a non-polar organic solvent, such as methylene chloride. The film may be prepared by utilizing a selected casting or deposition method and a controlled drying process. For example, the film may be prepared through a controlled drying processes, which include application of heat and/or radiation energy to the wet film matrix to form a visco-elastic  
20 structure, thereby controlling the uniformity of content of the film. The controlled drying processes can include air alone, heat alone or heat and air together contacting the top of the film or bottom of the film or the substrate supporting the cast or deposited or extruded film or contacting more than one surface at the same time or at different times during the drying process. Some of such processes are described in more detail in U.S. Patent No. 8,765,167 and U.S.  
25 Patent No. 8,652,378, which are incorporated by reference herein. Alternatively, the films may be extruded as described in U.S. Patent Publication No. 2005/0037055 A1, which is incorporated by reference herein.

A polymer included in the films may be water-soluble, water-swellaable, water-insoluble, or a combination of one or more either water-soluble, water-swellaable or water-insoluble  
30 polymers. The polymer may include cellulose, cellulose derivatives or gums. Specific examples of useful water-soluble polymers include, but are not limited to, polyethylene oxide, pullulan,

hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone, carboxymethyl cellulose, polyvinyl alcohol, sodium alginate, polyethylene glycol, xanthan gum, tragacanth gum, guar gum, acacia gum, arabic gum, polyacrylic acid, methylmethacrylate copolymer, carboxyvinyl copolymers, starch, gelatin, and combinations thereof. Specific examples of useful water-insoluble polymers include, but are not limited to, ethyl cellulose, hydroxypropyl ethyl cellulose, cellulose acetate phthalate, hydroxypropyl methyl cellulose phthalate and combinations thereof. For higher dosages, it may be desirable to incorporate a polymer that provides a high level of viscosity as compared to lower dosages.

As used herein the phrase "water-soluble polymer" and variants thereof refer to a polymer that is at least partially soluble in water, and desirably fully or predominantly soluble in water, or absorbs water. Polymers that absorb water are often referred to as being water-swellaable polymers. The materials useful with the present invention may be water-soluble or water-swellaable at room temperature and other temperatures, such as temperatures exceeding room temperature. Moreover, the materials may be water-soluble or water-swellaable at pressures less than atmospheric pressure. In some embodiments, films formed from such water-soluble polymers may be sufficiently water-soluble to be dissolvable upon contact with bodily fluids.

Other polymers useful for incorporation into the films include biodegradable polymers, copolymers, block polymers or combinations thereof. It is understood that the term "biodegradable" is intended to include materials that chemically degrade, as opposed to materials that physically break apart (i.e., bioerodable materials). The polymers incorporated in the films can also include a combination of biodegradable or bioerodable materials. Among the known useful polymers or polymer classes which meet the above criteria are: poly(glycolic acid) (PGA), poly(lactic acid) (PLA), polydioxanes, polyoxalates, poly(alpha-esters), polyanhydrides, polyacetates, polycaprolactones, poly(orthoesters), polyamino acids, polyaminocarbonates, polyurethanes, polycarbonates, polyamides, poly(alkyl cyanoacrylates), and mixtures and copolymers thereof. Additional useful polymers include, stereopolymers of L- and D-lactic acid, copolymers of bis(p-carboxyphenoxy)propane acid and sebacic acid, sebacic acid copolymers, copolymers of caprolactone, poly(lactic acid)/poly(glycolic acid)/polyethyleneglycol copolymers, copolymers of polyurethane and (poly(lactic acid)), copolymers of alpha-amino acids, copolymers of alpha-amino acids and caproic acid, copolymers of alpha-benzyl glutamate and polyethylene glycol, copolymers of succinate and poly(glycols), polyphosphazene,



polyhydroxy-alkanoates or mixtures thereof. The polymer matrix can include one, two, three, four or more components.

Although a variety of different polymers may be used, it is desired to select polymers that provide mucoadhesive properties to the film, as well as a desired dissolution and/or

5 disintegration rate. In particular, the time period for which it is desired to maintain the film in contact with the mucosal tissue depends on the type of pharmaceutically active component contained in the composition. Some pharmaceutically active components may only require a few minutes for delivery through the mucosal tissue, whereas other pharmaceutically active components may require up to several hours or even longer. Accordingly, in some embodiments, 10 one or more water-soluble polymers, as described above, may be used to form the film. In other embodiments, however, it may be desirable to use combinations of water-soluble polymers and polymers that are water-swellaable, water-insoluble and/or biodegradable, as provided above. The inclusion of one or more polymers that are water-swellaable, water-insoluble and/or biodegradable may provide films with slower dissolution or disintegration rates than films 15 formed from water-soluble polymers alone. As such, the film may adhere to the mucosal tissue for longer periods of time, such as up to several hours, which may be desirable for delivery of certain pharmaceutically active components.

Desirably, an individual film dosage of the pharmaceutical film can have a suitable thickness, and small size, which is between about 0.0625-3 inch by about 0.0625-3 inch. The 20 film size can also be greater than 0.0625 inch, greater than 0.5 inch, greater than 1 inch, greater than 2 inches, about 3 inches, and greater than 3 inches, less than 3 inches, less than 2 inches, less than 1 inch, less than 0.5 inch, less than 0.0625 inch in at least one aspect, or greater than 0.0625 inch, greater than 0.5 inch, greater than 1 inch, greater than 2 inches, or greater than 3 inches, about 3 inches, less than 3 inches, less than 2 inches, less than 1 inch, less than 0.5 inch, 25 less than 0.0625 inch in another aspect. The aspect ratio, including thickness, length, and width can be optimized by a person of ordinary skill in the art based on the chemical and physical properties of the polymeric matrix, the active pharmaceutical ingredient, dosage, enhancer, and other additives involved as well as the dimensions of the desired dispensing unit. The film dosage should have good adhesion when placed in the buccal cavity or in the sublingual region 30 of the user. Further, the film dosage should disperse and dissolve at a moderate rate, most desirably dispersing within about 1 minute and dissolving within about 3 minutes. In some

embodiments, the film dosage may be capable of dispersing and dissolving at a rate of between about 1 to about 30 minutes, for example, about 1 to about 20 minutes, or more than 1 minute, more than 5 minutes, more than 7 minutes, more than 10 minutes, more than 12 minutes, more than 15 minutes, more than 20 minutes, more than 30 minutes, about 30 minutes, or less than 30 minutes, less than 20 minutes, less than 15 minutes, less than 12 minutes, less than 10 minutes, less than 7 minutes, less than 5 minutes, or less than 1 minute. Sublingual dispersion rates may be shorter than buccal dispersion rates.

For instance, in some embodiments, the films may include polyethylene oxide alone or in combination with a second polymer component. The second polymer may be another water-soluble polymer, a water-swellaable polymer, a water-insoluble polymer, a biodegradable polymer or any combination thereof. Suitable water-soluble polymers include, without limitation, any of those provided above. In some embodiments, the water-soluble polymer may include hydrophilic cellulosic polymers, such as hydroxypropyl cellulose and/or hydroxypropylmethyl cellulose. In some embodiments, one or more water-swellaable, water-insoluble and/or biodegradable polymers also may be included in the polyethylene oxide-based film. Any of the water-swellaable, water-insoluble or biodegradable polymers provided above may be employed. The second polymer component may be employed in amounts of about 0% to about 80% by weight in the polymer component, more specifically about 30% to about 70% by weight, and even more specifically about 40% to about 60% by weight, including greater than 5%, greater than 10%, greater than 15%, greater than 20%, greater than 30%, greater than 40%, greater than 50%, greater than 60%, and greater than 70%, about 70%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10% or less than 5% by weight.

Additives may be included in the films. Examples of classes of additives include preservatives, antimicrobials, excipients, lubricants, buffering agents, stabilizers, blowing agents, pigments, coloring agents, fillers, bulking agents, sweetening agents, flavoring agents, fragrances, release modifiers, adjuvants, plasticizers, flow accelerators, mold release agents, polyols, granulating agents, diluents, binders, buffers, absorbents, glidants, adhesives, anti-adherents, acidulants, softeners, resins, demulcents, solvents, surfactants, emulsifiers, elastomers, anti-tacking agents, anti-static agents and mixtures thereof. These additives may be added with the pharmaceutically active component(s). As used herein, the term “stabilizer” means an

excipient capable of preventing aggregation or other physical degradation, as well as chemical degradation, of the active pharmaceutical ingredient, another excipient, or the combination thereof.

Stabilizers may also be classified as antioxidants, sequestrants, pH modifiers, emulsifiers and/or surfactants, and UV stabilizers.

Antioxidants (i.e., pharmaceutically compatible compound(s) or composition(s) that decelerates, inhibits, interrupts and/or stops oxidation processes) include, in particular, the following substances: tocopherols and the esters thereof, sesamol of sesame oil, coniferyl benzoate of benzoin resin, nordihydroguaietic resin and nordihydroguaiaretic acid (NDGA), gallates (among others, methyl, ethyl, propyl, amyl, butyl, lauryl gallates), butylated hydroxyanisole (BHA/BHT, also butyl-p-cresol); ascorbic acid and salts and esters thereof (for example, acorbyl palmitate), erythorbic acid (isoascorbic acid) and salts and esters thereof, monothioglycerol, sodium formaldehyde sulfoxylate, sodium metabisulfite, sodium bisulfite, sodium sulfite, potassium metabisulfite, butylated hydroxyanisole, butylated hydroxytoluene (BHT), propionic acid. Typical antioxidants are tocopherol such as, for example,  $\alpha$ -tocopherol and the esters thereof, butylated hydroxytoluene and butylated hydroxyanisole. The terms "tocopherol" also includes esters of tocopherol. A known tocopherol is  $\alpha$ -tocopherol. The term " $\alpha$ -tocopherol" includes esters of  $\alpha$ -tocopherol (for example,  $\alpha$ -tocopherol acetate).

Sequestrants (i.e., any compounds which can engage in host-guest complex formation with another compound, such as the active ingredient or another excipient; also referred to as a sequestering agent) include calcium chloride, calcium disodium ethylene diamine tetra-acetate, glucono delta-lactone, sodium gluconate, potassium gluconate, sodium tripolyphosphate, sodium hexametaphosphate, and combinations thereof. Sequestrants also include cyclic oligosaccharides, such as cyclodextrins, cyclomannins (5 or more  $\alpha$ -D-mannopyranose units linked at the 1,4 positions by  $\alpha$  linkages), cyclogalactins (5 or more  $\beta$ -D-galactopyranose units linked at the 1,4 positions by  $\beta$  linkages), cycloaltrins (5 or more  $\alpha$ -D-altropyranose units linked at the 1,4 positions by  $\alpha$  linkages), and combinations thereof.

pH modifiers include acids (e.g., tartaric acid, citric acid, lactic acid, fumaric acid, phosphoric acid, ascorbic acid, acetic acid, succinic acid, adipic acid and maleic acid), acidic amino acids (e.g., glutamic acid, aspartic acid, etc.), inorganic salts (alkali metal salt, alkaline earth metal salt, ammonium salt, etc.) of such acidic substances, a salt of such acidic substance

with an organic base (e.g., basic amino acid such as lysine, arginine and the like, meglumine and the like), and a solvate (e.g., hydrate) thereof. Other examples of pH modifiers include silicified microcrystalline cellulose, magnesium aluminometasilicate, calcium salts of phosphoric acid (e.g., calcium hydrogen phosphate anhydrous or hydrate, calcium, sodium or potassium carbonate or hydrogencarbonate and calcium lactate or mixtures thereof), sodium and/or calcium salts of carboxymethyl cellulose, cross-linked carboxymethylcellulose (e.g., croscarmellose sodium and/or calcium), polacrilin potassium, sodium and/or calcium alginate, docusate sodium, magnesium calcium, aluminium or zinc stearate, magnesium palmitate and magnesium oleate, sodium stearyl fumarate, and combinations thereof.

Examples of emulsifiers and/or surfactants include poloxamers or pluronics, polyethylene glycols, polyethylene glycol monostearate, polysorbates, sodium lauryl sulfate, polyethoxylated and hydrogenated castor oil, alkyl polyoside, a grafted water soluble protein on a hydrophobic backbone, lecithin, glyceryl monostearate, glyceryl monostearate/polyoxyethylene stearate, ketostearyl alcohol/sodium lauryl sulfate, carbomer, phospholipids, (C<sub>10</sub>-C<sub>20</sub>)-alkyl and alkylene carboxylates, alkyl ether carboxylates, fatty alcohol sulfates, fatty alcohol ether sulfates, alkylamide sulfates and sulfonates, fatty acid alkylamide polyglycol ether sulfates, alkanesulfonates and hydroxyalkanesulfonates, olefinsulfonates, acyl esters of isethionates,  $\alpha$ -sulfo fatty acid esters, alkylbenzenesulfonates, alkylphenol glycol ether sulfonates, sulfosuccinates, sulfosuccinic monoesters and diesters, fatty alcohol ether phosphates, protein/fatty acid condensation products, alkyl monoglyceride sulfates and sulfonates, alkylglyceride ether sulfonates, fatty acid methyltaurides, fatty acid sarcosinates, sulfuricinoleates, and acylglutamates, quaternary ammonium salts (e.g., di-(C<sub>10</sub>-C<sub>24</sub>)-alkyl-dimethylammonium chloride or bromide), (C<sub>10</sub>-C<sub>24</sub>)-alkyl-dimethylethylammonium chloride or bromide, (C<sub>10</sub>-C<sub>24</sub>)-alkyl-trimethylammonium chloride or bromide (e.g., cetyltrimethylammonium chloride or bromide), (C<sub>10</sub>-C<sub>24</sub>)-alkyl-dimethylbenzylammonium chloride or bromide (e.g., (C<sub>12</sub>-C<sub>18</sub>)-alkyl-dimethylbenzylammonium chloride), N-(C<sub>10</sub>-C<sub>18</sub>)-alkyl-pyridinium chloride or bromide (e.g., N-(C<sub>12</sub>-C<sub>16</sub>)-alkyl-pyridinium chloride or bromide), N-(C<sub>10</sub>-C<sub>18</sub>)-alkyl-isoquinolinium chloride, bromide or monoalkyl sulfate, N-(C<sub>12</sub>-C<sub>18</sub>)-alkyl-polyoylaminoformylmethylpyridinium chloride, N-(C<sub>12</sub>-C<sub>18</sub>)-alkyl-N-methylmorpholinium chloride, bromide or monoalkyl sulfate, N-(C<sub>12</sub>-C<sub>18</sub>)-alkyl-N-ethylmorpholinium chloride, bromide or monoalkyl sulfate, (C<sub>16</sub>-C<sub>18</sub>)-alkyl-pentaoxethylammonium chloride,

diisobutylphenoxyethoxyethyl dimethylbenzylammonium chloride, salts of N,N-diethylaminoethylstearylamine and -oleylamine with hydrochloric acid, acetic acid, lactic acid, citric acid, phosphoric acid, N-acylaminoethyl-N,N-diethyl-N-methylammonium chloride, bromide or monoalkyl sulfate, and N-acylaminoethyl-N,N-diethyl-N-benzylammonium chloride, bromide or monoalkyl sulfate (in the foregoing, "acyl" standing for, e.g., stearyl or oleyl), and combinations thereof.

Examples of UV stabilizers include UV absorbers (e.g., benzophenones), UV quenchers (i.e., any compound that dissipates UV energy as heat, rather than allowing the energy to have a degradation effect), scavengers (i.e., any compound that eliminates free radicals resulting from exposure to UV radiation), and combinations thereof.

In other embodiments, stabilizers include ascorbyl palmitate, ascorbic acid, alpha tocopherol, butylated hydroxytoluene, butylated hydroxyanisole, cysteine HCl, citric acid, ethylenediamine tetra acetic acid (EDTA), methionine, sodium citrate, sodium ascorbate, sodium thiosulfate, sodium metabisulfite, sodium bisulfite, propyl gallate, glutathione, thioglycerol, singlet oxygen quenchers, hydroxyl radical scavengers, hydroperoxide removing agents, reducing agents, metal chelators, detergents, chaotropes, and combinations thereof. "Singlet oxygen quenchers" include, but are not limited to, alkyl imidazoles (e.g., histidine, L-carnosine, histamine, imidazole 4-acetic acid), indoles (e.g., tryptophan and derivatives thereof, such as N-acetyl-5-methoxytryptamine, N-acetylserotonin, 6-methoxy-1,2,3,4-tetrahydro-beta-carboline), sulfur-containing amino acids (e.g., methionine, ethionine, djenkolic acid, lanthionine, N-formyl methionine, felinine, S-allyl cysteine, S-aminoethyl-L-cysteine), phenolic compounds (e.g., tyrosine and derivatives thereof), aromatic acids (e.g., ascorbate, salicylic acid, and derivatives thereof), azide (e.g., sodium azide), tocopherol and related vitamin E derivatives, and carotene and related vitamin A derivatives. "Hydroxyl radical scavengers" include, but are not limited to azide, dimethyl sulfoxide, histidine, mannitol, sucrose, glucose, salicylate, and L-cysteine. "Hydroperoxide removing agents" include, but are not limited to catalase, pyruvate, glutathione, and glutathione peroxidases. "Reducing agents" include, but are not limited to, cysteine and mercaptoethylene. "Metal chelators" include, but are not limited to, EDTA, EGTA, o-phenanthroline, and citrate. "Detergents" include, but are not limited to, SDS and sodium lauryl sarcosyl. "Chaotropes" include, but are not limited to guanidinium hydrochloride, isothiocyanate, urea, and formamide. As discussed herein, stabilizers can be present in 0.0001%-50% by

weight, including greater than 0.0001%, greater than 0.001%, greater than 0.01%, greater than 0.1%, greater than 1%, greater than 5%, greater than 10%, greater than 20%, greater than 30%, greater than 40%, greater than 50%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 1%, less than 0.1%, less than 0.01%, less than 0.001%, or less than 0.0001% by weight.

Useful additives can include, for example, gelatin, vegetable proteins such as sunflower protein, soybean proteins, cotton seed proteins, peanut proteins, grape seed proteins, whey proteins, whey protein isolates, blood proteins, egg proteins, acrylated proteins, water-soluble polysaccharides such as alginates, carrageenans, guar gum, agar-agar, xanthan gum, gellan gum, gum arabic and related gums (gum ghatti, gum karaya, gum tragacanth), pectin, water-soluble derivatives of cellulose: alkylcelluloses hydroxyalkylcelluloses and hydroxyalkylalkylcelluloses, such as methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylmethylcellulose, hydroxypropylmethylcellulose, hydroxybutylmethylcellulose, cellulose esters and hydroxyalkylcellulose esters such as cellulose acetate phthalate (CAP), hydroxypropylmethylcellulose (HPMC); carboxyalkylcelluloses, carboxyalkylalkylcelluloses, carboxyalkylcellulose esters such as carboxymethylcellulose and their alkali metal salts; water-soluble synthetic polymers such as polyacrylic acids and polyacrylic acid esters, polymethacrylic acids and polymethacrylic acid esters, polyvinylacetates, polyvinylalcohols, polyvinylacetatephthalates (PVAP), polyvinylpyrrolidone (PVP), PVA/vinyl acetate copolymer, and polycrotonic acids; also suitable are phthalated gelatin, gelatin succinate, crosslinked gelatin, shellac, water-soluble chemical derivatives of starch, cationically modified acrylates and methacrylates possessing, for example, a tertiary or quaternary amino group, such as the diethylaminoethyl group, which may be quaternized if desired; or other similar polymers.

The additional components can range up to about 80%, desirably about 0.005% to 50% and more desirably within the range of 1% to 20% based on the weight of all composition components, including greater than 1%, greater than 5%, greater than 10%, greater than 20%, greater than 30%, greater than 40%, greater than 50%, greater than 60%, greater than 70%, about 80%, greater than 80%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, about 3%, or less than 1%.

Other additives can include anti-tacking, flow agents and opacifiers, such as the oxides of magnesium aluminum, silicon, titanium, etc. desirably in a concentration range of about 0.005%

to about 5% by weight and desirably about 0.02% to about 2% based on the weight of all film components, including greater than 0.02%, greater than 0.2%, greater than 0.5%, greater than 1%, greater than 1.5%, greater than 2%, greater than 4%, about 5%, greater than 5%, less than 4%, less than 2%, less than 1%, less than 0.5%, less than 0.2%, or less than 0.02%.

5           In certain embodiments, the composition can include plasticizers, which can include polyalkylene oxides, such as polyethylene glycols, polypropylene glycols, polyethylene-propylene glycols, organic plasticizers with low molecular weights, such as glycerol, glycerol monoacetate, diacetate or triacetate, triacetin, polysorbate, cetyl alcohol, propylene glycol, sugar alcohols sorbitol, sodium diethylsulfosuccinate, triethyl citrate, tributyl citrate, phytoextracts, 10 fatty acid esters, fatty acids, oils and the like, added in concentrations ranging from about 0.1% to about 40%, and desirably ranging from about 0.5% to about 20% based on the weight of the composition including greater than 0.5%, greater than 1%, greater than 1.5%, greater than 2%, greater than 4%, greater than 5%, greater than 10%, greater than 15%, about 20%, greater than 20%, less than 20%, less than 15%, less than 10%, less than 5%, less than 4%, less than 2%, less 15 than 1%, and less than 0.5%. There may further be added compounds to improve the texture properties of the film material such as animal or vegetable fats, desirably in their hydrogenated form. The composition can also include compounds to improve the textural properties of the product. Other ingredients can include binders which contribute to the ease of formation and general quality of the films. Non-limiting examples of binders include starches, natural gums, 20 pregelatinized starches, gelatin, polyvinylpyrrolidone, methylcellulose, sodium carboxymethylcellulose, ethylcellulose, polyacrylamides, polyvinylpyrrolidone, or polyvinylalcohols.

Further potential additives include solubility enhancing agents, such as substances that form inclusion compounds with active components. Such agents may be useful in improving the 25 properties of very insoluble and/or unstable actives. In general, these substances are doughnut-shaped molecules with hydrophobic internal cavities and hydrophilic exteriors. Insoluble and/or instable pharmaceutically active components may fit within the hydrophobic cavity, thereby producing an inclusion complex, which is soluble in water. Accordingly, the formation of the inclusion complex permits very insoluble and/or unstable pharmaceutically active components to 30 be dissolved in water. A particularly desirable example of such agents are cyclodextrins, which

are cyclic carbohydrates derived from starch. Other similar substances, however, are considered well within the scope of the present invention.

Suitable coloring agents include food, drug and cosmetic colors (FD&C), drug and cosmetic colors (D&C), or external drug and cosmetic colors (Ext. D&C). These colors are dyes, 5 their corresponding lakes, and certain natural and derived colorants. Lakes are dyes absorbed on aluminum hydroxide. Other examples of coloring agents include known azo dyes, organic or inorganic pigments, or coloring agents of natural origin. Inorganic pigments are preferred, such as the oxides of iron or titanium, these oxides, being added in concentrations ranging from about 0.001 to about 10%, and preferably about 0.5 to about 3%, including greater than 0.001%, 10 greater than 0.01%, greater than 0.1%, greater than 0.5%, greater than 1%, greater than 2%, greater than 5%, about 10%, greater than 10%, less than 10%, less than 5%, less than 2%, less than 1%, less than 0.5%, less than 0.1%, less than 0.01%, or less than 0.001%, based on the weight of all the components.

Flavors may be chosen from natural and synthetic flavoring liquids. An illustrative list of 15 such agents includes volatile oils, synthetic flavor oils, flavoring aromatics, oils, liquids, oleoresins or extracts derived from plants, leaves, flowers, fruits, stems and combinations thereof. A non-limiting representative list of examples includes mint oils, cocoa, and citrus oils such as lemon, orange, lime and grapefruit and fruit essences including apple, pear, peach, grape, strawberry, raspberry, cherry, plum, pineapple, apricot or other fruit flavors. Other useful 20 flavorings include aldehydes and esters such as benzaldehyde (cherry, almond), citral i.e., aliphatic citral (lemon, lime), neral, i.e., beta-citral (lemon, lime), decanal (orange, lemon), aldehyde C-8 (citrus fruits), aldehyde C-9 (citrus fruits), aldehyde C-12 (citrus fruits), tolyl aldehyde (cherry, almond), 2,6-dimethyloctanol (green fruit), and 2-dodecenal (citrus, mandarin), combinations thereof and the like.

25 The sweeteners may be chosen from the following non-limiting list: glucose (corn syrup), dextrose, invert sugar, fructose, and combinations thereof, saccharin and its various salts such as the sodium salt; dipeptide based sweeteners such as aspartame, neotame, advantame; dihydrochalcone compounds, glycyrrhizin; Stevia Rebaudiana (Stevioside); chloro derivatives of sucrose such as sucralose; sugar alcohols such as sorbitol, mannitol, xylitol, and the like. Also 30 contemplated are hydrogenated starch hydrolysates and the synthetic sweetener 3,6-dihydro-6-methyl-1,1,2,3-oxathiazin-4-one-2,2-dioxide, particularly the potassium salt (acesulfame-K),



and sodium and calcium salts thereof, and natural intensive sweeteners, such as Lo Han Kuo. Other sweeteners may also be used.

Anti-foaming and/or de-foaming components may also be used with the films. These components aid in the removal of air, such as entrapped air, from the film-forming compositions.

5 Such entrapped air may lead to non-uniform films. Simethicone is one particularly useful anti-foaming and/or de-foaming agent. The present invention, however, is not so limited and other suitable anti-foam and/or de-foaming agents may be used. Simethicone and related agents may be employed for densification purposes. More specifically, such agents may facilitate the removal of voids, air, moisture, and similar undesired components, thereby providing denser and  
10 thus more uniform films. Agents or components which perform this function can be referred to as densification or densifying agents. As described above, entrapped air or undesired components may lead to non-uniform films.

Any other optional components described in commonly assigned U.S. Patent No. 7,425,292 and U.S. Patent No. 8,765,167, referred to above, also may be included in the films  
15 described herein.

The film compositions further desirably contains a buffer so as to control the pH of the film composition. Any desired level of buffer may be incorporated into the film composition so as to provide the desired pH level encountered as the pharmaceutically active component is released from the composition. The buffer is preferably provided in an amount sufficient to  
20 control the release from the film and/or the absorption into the body of the pharmaceutically active component. In some embodiments, the buffer may include sodium citrate, citric acid, bitartrate salt and combinations thereof.

The pharmaceutical films described herein may be formed via any desired process. Suitable processes are set forth in U.S. Patent Nos. 8,652,378, 7,425,292 and 7,357,891, which  
25 are incorporated by reference herein. In one embodiment, the film dosage composition is formed by first preparing a wet composition, the wet composition including a polymeric carrier matrix and a therapeutically effective amount of a pharmaceutically active component. The wet composition is cast into a film and then sufficiently dried to form a self-supporting film composition. The wet composition may be cast into individual dosages, or it may be cast into a  
30 sheet, where the sheet is then cut into individual dosages.

The pharmaceutical composition can adhere to a mucosal surface. The present invention finds particular use in the localized treatment of body tissues, diseases, or wounds which may have moist surfaces and which are susceptible to bodily fluids, such as the mouth, the vagina, organs, or other types of mucosal surfaces. The composition carries a pharmaceutical, and upon application and adherence to the mucosal surface, offers a layer of protection and delivers the pharmaceutical to the treatment site, the surrounding tissues, and other bodily fluids. The composition provides an appropriate residence time for effective drug delivery at the treatment site, given the control of erosion in aqueous solution or bodily fluids such as saliva, and the slow, natural erosion of the film concomitant or subsequent to the delivery.

The residence time of the composition depends on the erosion rate of the water erodable polymers used in the formulation and their respective concentrations. The erosion rate may be adjusted, for example, by mixing together components with different solubility characteristics or chemically different polymers, such as hydroxyethyl cellulose and hydroxypropyl cellulose; by using different molecular weight grades of the same polymer, such as mixing low and medium molecular weight hydroxyethyl cellulose; by using excipients or plasticizers of various lipophilic values or water solubility characteristics (including essentially insoluble components); by using water soluble organic and inorganic salts; by using crosslinking agents such as glyoxal with polymers such as hydroxyethyl cellulose for partial crosslinking; or by post-treatment irradiation or curing, which may alter the physical state of the film, including its crystallinity or phase transition, once obtained. These strategies might be employed alone or in combination in order to modify the erosion kinetics of the film. Upon application, the pharmaceutical composition film adheres to the mucosal surface and is held in place. Water absorption softens the composition, thereby diminishing the foreign body sensation. As the composition rests on the mucosal surface, delivery of the drug occurs. Residence times may be adjusted over a wide range depending upon the desired timing of the delivery of the chosen pharmaceutical and the desired lifespan of the carrier. Generally, however, the residence time is modulated between about a few seconds to about a few days. Preferably, the residence time for most pharmaceuticals is adjusted from about 5 seconds to about 24 hours. More preferably, the residence time is adjusted from about 5 seconds to about 30 minutes. In addition to providing drug delivery, once the composition adheres to the mucosal surface, it also provides protection to the treatment site, acting as an

erodable bandage. Lipophilic agents can be designed to slow down erodability to decrease disintegration and dissolution.

It is also possible to adjust the kinetics of erodability of the composition by adding excipients which are sensitive to enzymes such as amylase, very soluble in water such as water  
5 soluble organic and inorganic salts. Suitable excipients may include the sodium and potassium salts of chloride, carbonate, bicarbonate, citrate, trifluoroacetate, benzoate, phosphate, fluoride, sulfate, or tartrate. The amount added can vary depending upon how much the erosion kinetics is to be altered as well as the amount and nature of the other components in the composition.

Emulsifiers typically used in the water-based emulsions described above are, preferably,  
10 either obtained in situ if selected from the linoleic, palmitic, myristoleic, lauric, stearic, cetoleic or oleic acids and sodium or potassium hydroxide, or selected from the laurate, palmitate, stearate, or oleate esters of sorbitol and sorbitol anhydrides, polyoxyethylene derivatives including monooleate, monostearate, monopalmitate, monolaurate, fatty alcohols, alkyl phenols, allyl ethers, alkyl aryl ethers, sorbitan monostearate, sorbitan monooleate and/or sorbitan  
15 monopalmitate.

The amount of pharmaceutically active component to be used depends on the desired treatment strength and the composition of the layers, although preferably, the pharmaceutical component comprises from about 0.001% to about 99%, more preferably from about 0.003 to about 75%, and most preferably from about 0.005% to about 50% by weight of the composition,  
20 including, more than 0.005%, more than 0.05%, more than 0.5%, more than 1%, more than 5%, more than 10%, more than 15%, more than 20%, more than 30%, about 50%, more than 50%, less than 50%, less than 30%, less than 20%, less than 15%, less than 10%, less than 5%, less than 1%, less than 0.5%, less than 0.05%, or less than 0.005%. The amounts of other components may vary depending on the drug or other components but typically these components comprise  
25 no more than 50%, preferably no more than 30%, and most preferably no more than 15% by total weight of the composition.

The thickness of the film may vary, depending on the thickness of each of the layers and the number of layers. As stated above, both the thickness and amount of layers may be adjusted in order to vary the erosion kinetics. Preferably, if the composition has only two layers, the  
30 thickness ranges from 0.005 mm to 2 mm, preferably from 0.01 to 1 mm, and more preferably from 0.1 to 0.5 mm, including greater than 0.1 mm, greater than 0.2 mm, about 0.5 mm, greater

than 0.5 mm, less than 0.5 mm, less than 0.2 mm, or less than 0.1 mm. The thickness of each layer may vary from 10 to 90% of the overall thickness of the layered composition, and preferably varies from 30 to 60%, including greater than 10%, greater than 20%, greater than 30%, greater than 40%, greater than 50%, greater than 70%, greater than 90%, about 90%, less  
5 than 90%, less than 70%, less than 50%, less than 40%, less than 30%, less than 20%, or less than 10%. Thus, the preferred thickness of each layer may vary from 0.01 mm to 0.9 mm, or from 0.03 to 0.5 mm.

As one skilled in the art will appreciate, when systemic delivery, e.g., transmucosal or transdermal delivery is desired, the treatment site may include any area in which the film is  
10 capable of delivery and/or maintaining a desired level of pharmaceutical in the blood, lymph, or other bodily fluid. Typically, such treatment sites include the oral, esophageal, aural, ocular, anal, nasal, and vaginal mucosal tissue, as well as, the skin. If the skin is to be employed as the treatment site, then usually larger areas of the skin wherein movement will not disrupt the adhesion of the film, such as the upper arm or thigh, are preferred.

15 The pharmaceutical composition can also be used as a wound dressing. By offering a physical, compatible, oxygen and moisture permeable, flexible barrier which can be washed away, the film can not only protect a wound but also deliver a pharmaceutical in order to promote healing, aseptic, scarification, to ease the pain or to improve globally the condition of the sufferer. Some of the: examples given below are well suited for an application to the skin or a  
20 wound. As one skilled in the art will appreciate, the formulation might require incorporating a specific hydrophilic/hygroscopic excipient which would help in maintaining good adhesion on dry skin over an extended period of time. Another advantage of the present invention when utilized in this manner is that if one does not wish that the film be noticeable on the skin, then no dyes or colored substances need be used. If, on the other hand, one desires that the film be  
25 noticeable, a dye or colored substance may be employed.

While the pharmaceutical composition can adhere to mucosal tissues, which are wet tissues by nature, it can also be used on other surfaces such as skin or wounds. The pharmaceutical film can adhere to the skin if prior to application the skin is wet with an aqueous-based fluid such as water, saliva, wound drainage or perspiration. The film can adhere to the skin  
30 until it erodes due to contact with water by, for example, rinsing, showering, bathing or washing. The film may also be readily removed by peeling without significant damage to tissue.

A Franz diffusion cell is an in vitro skin permeation assay used in formulation development. The Franz diffusion cell apparatus (**Figure 1A**) consists of two chambers separated by a membrane of, for example, animal or human tissue. The test product is applied to the membrane via the top chamber. The bottom chamber contains fluid from which samples are taken at regular intervals for analysis to determine the amount of active that has permeated the membrane. Referring to **Figure 1A**, a Franz diffusion cell 100 includes a donor compound 101, a donor chamber 102, a membrane 103, sampling port 104, receptor chamber 105, stir bar 106, and a heater/circulator 107.

Referring to **Figure 1B**, a pharmaceutical composition is a film 100 comprising a polymeric matrix 200, the pharmaceutically active component 300 being contained in the polymeric matrix. The film can include a permeation enhancer 400.

Referring to **Figures 2A** and **2B**, the graphs show the permeation of an active material from a composition. The graph shows that for the epinephrine base – solubilized in-situ vs. the inherently soluble epinephrine bitartrate, no meaningful differences were observed. Epinephrine bitartrate was selected for further development based on ease of processing. Flux is derived as slope of the amount permeated as a function of time. Steady state flux is taken from the plateau of flux vs time curve multiplied by the volume of receiver media and normalized for permeation area.

Referring to **Figure 2A**, this graph shows average amount of active material permeated vs. time, with 8.00 mg/mL epinephrine bitartrate and 4.4 mg/mL epinephrine base solubilized.

Referring to **Figure 2B**, this graph shows average flux vs. time, with 8.00 mg/mL epinephrine bitartrate and 4.4 mg/mL epinephrine base solubilized.

Referring to **Figure 3**, this graph shows ex-vivo permeation of epinephrine bitartrate as a function of concentration. The study compared concentrations of 4 mg/mL, 8 mg/mL, 16 mg/mL and 100 mg/mL. Results showed that increasing concentration resulted in increased permeation, and level of enhancement diminishes at higher loading.

Referring to **Figure 4**, this graph shows permeation of epinephrine bitartrate as a function of solution pH. Acidic conditions explored to promote stability. The results compared epinephrine bitartrate pH 3 buffer and epinephrine bitartrate pH 5 buffer, and found that the epinephrine bitartrate pH 5 buffer was slightly favorable.

Referring to **Figure 5**, this graph shows the influence of enhancers on permeation of epinephrine, indicated as amount permeated as a function of time. Multiple enhancers were screened, including Labrasol, capryol 90, Plurol Oleique, Labrafil, TDM, SGDC, Gelucire 44/14 and clove oil. Significant impact on time to onset and steady state flux was achieved, and surprisingly enhanced permeation was achieved for clove oil and Labrasol.

Referring to **Figure 6A** and **6B**, these graphs show the release of epinephrine on polymer platforms and the effect of enhancers on its release, indicated as amount permeated (in  $\mu\text{g}$ ) vs. time. **Figure 6A** shows the epinephrine release from different polymer platforms. **Figure 6B** shows the impact of enhancers on epinephrine release.

Referring to **Figure 7**, this graph shows a pharmacokinetic model in the male Yucatan, miniature swine. The study compares a 0.3 mg Epipen, a 0.12 mg Epinephrine IV and a placebo film.

Referring to **Figure 8**, this graphs shows the impact of no enhancer on the concentration profiles of a 40 mg epinephrine film vs, a 0.3 mg Epipen.

Referring to **Figure 9**, this graph shows the impact of Enhancer A (Labrasol) on the concentration profiles of a 40 mg epinephrine film vs, a 0.3 mg Epipen. Referring to **Figure 10**, this graph shows the impact of Enhancer L (clove oil) on the concentration profiles of two 40 mg Epinephrine films (10-1-1) and (11-1-1) vs. a 0.3 mg Epipen.

Referring to **Figure 11**, This graph shows the impact of Enhancer L(clove oil) and film dimension (10-1-1 thinner bigger film and 11-1-1 thicker smaller film) on the concentration profiles of 40 mg Epinephrine films vs. a 0.3 mg Epipen.

Referring to **Figure 12**, this graph shows the concentration profiles for varying doses of Epinephrine films in a constant matrix for Enhancer L (clove oil) vs. a 0.3 mg Epipen.

Referring to **Figure 13**, the graph shows the concentration profiles for varying doses of Epinephrine films in a constant matrix for Enhancer L (clove oil) vs. a 0.3 mg Epipen.

Referring to **Figure 14**, the graph shows the concentration profiles for varying doses of Epinephrine films in a constant matrix for Enhancer A (Labrasol) vs. a 0.3 mg Epipen.

Referring to **Figure 15**, this graph shows the impact of Farnesol and Farnesol in combination with Linoleic Acid on plasma concentration profiles of 40 mg Epinephrine Films vs. a 0.3 mg Epipen.

Referring to **Figure 16**, this graph shows the impact of Farnesol and Farnesol in combination with Linoleic Acid on plasma concentration profiles of 40 mg Epinephrine Films vs. a 0.3 mg Epipen.

Referring to **Figure 17**, this graph shows the impact of Farnesol in combination with  
5 Linoleic Acid on plasma concentration profiles of 40 mg Epinephrine Films vs. a 0.3 mg Epipen.

Referring to **Figure 18**, this graph shows the impact of Farnesol and Farnesol in combination with Linoleic Acid on plasma concentration profiles of 40 mg Epinephrine Films vs. a 0.3 mg Epipen. The following examples are provided to illustrate pharmaceutical compositions, as well as, methods of making and using, pharmaceutical compositions and  
10 devices described herein.

## EXAMPLES

### Example 1

#### Permeation Enhancers - Epinephrine

15 Permeation enhancement was studied using a number of permeation enhancers with Epinephrine Bitartrate 16.00 mg/mL concentration. The results show flux enhancement represented in the data below. For 100% Eugenol and 100% Clove Oil, the results showed steady state flux reached significantly earlier along with an unexpectedly heightened % flux enhancement.

20

Donor Solution (16.00mg/mL Epinephrine Bitartrate + enhancer)	Average Steady State Flux (ug/cm <sup>2</sup> *min)	% Flux enhancement	Permeability
			Coefficient (cm/s)
Epinephrine Bitartrate ,no enhancer	1.3173	N/A	1.37E-06
3% Clove Oil	8.2704	527.84	8.61E-06
3% Clove Oil Repeat	5.3776	308.24	5.60E-06
3% Eugenol	7.1311	441.35	7.43E-06
3% Eugenyl Acetate	1.8945	43.82	1.97E-06
3% B-Caryophyllene	3.5200	167.22	3.67E-06
0.3% Eugenol*	3.9735	201.65	4.14E-06
100% Eugenol <sup>1</sup>	36.8432	2696.92	3.84E-05
0.3% Clove Oil*	3.6806	179.41	3.83E-06
100% Clove Oil <sup>1</sup>	52.5304	3887.81	5.47E-05
3% Phenol	4.5790	247.61	4.77E-06
3% Phenol Repeat	4.1753	216.97	4.35E-06
3% Linoleic Acid	2.1788	65.40	2.27E-06
50% Clove Oil	2.5673	94.89	2.67E-06
0.3% Labrasol	3.5221	167.38	3.67E-06
3% Vanillyl Alcohol+ 6% Ethanol	1.10243	-16.31	1.15E-06
3% Safrole	2.60634	97.86	2.71E-06
3% Oleic Acid	2.06597	56.84	2.15E-06
3% Oleic Acid + 1% PEG200	2.73655	107.74	2.85E-06
3% Benzyl Alcohol	1.38455	5.11	1.44E-06

<sup>1</sup> steady state flux reached at much earlier time point

\* 0.3% Eugenol vs 0.3% Clove -similar flux rates to one another

For these examples, clove oil was obtained from clove leaf. Similar results may be obtained from clove oil from clove bud and/or clove stem. Based on this data, similar permeability enhancement results can be expected from pharmaceutical compounds structurally similar to epinephrine.

5



## Example 2

### General Permeation Procedure – Ex vivo Permeation Study Protocol

In one example, a permeation procedure is conducted as follows. A temperature bath is set to 37° C, and receiver media is placed in a water bath to adjust the temperature and begin  
5 degassing. A franz diffusion cell is obtained and prepared. The franz diffusion cell includes a donor compound, a donor chamber, a membrane, sampling port, receptor chamber, stir bar, and a heater/circulator. A stir bar is inserted into a franz diffusion cell. Tissue is placed over the franz diffusion cell, and it is ensured that the tissue covers the entire area with an overlap onto a glass joint. The top of a diffusion cell is placed over the tissue, and the top of the cell is clamped to  
10 the bottom. About 5 mL of receptor media is loaded into the receiver area to ensure that no air bubbles are trapped in the received portion of the cell. This ensures that all 5mL can fit into the receiver area. Stirring is begun, and temperature is allowed to equilibrate for about 20 minutes. Meanwhile, High Performance Liquid Chromatography (HPLC) vials are labelled by cell number and time point. One must then check again for air bubbles as the solution will degas  
15 during heating.

If testing films, one can perform the following next steps: (1) weigh films, punch to match diffusion area (or smaller), reweigh, record pre- and post-punching weight; (2) wet a donor area with approximately 100 µL of phosphate buffer; (3) place film on a donor surface, top with 400 µL of phosphate buffer, and start timers.

20 For solution studies, one can perform the following steps: (1) using a micropipette, dispense 500 µL of the solution into each donor cell, start the timers; (2) sample 200 µL at the following time points (time = 0 min, 20 min, 40 min, 60 min, 120 min, 180 min, 240 min, 300 min, 360 min), and place in labelled HPLC vials, ensure no air is trapped in the bottom of the vial by tapping the closed vials; (3) replace each sample time with 200 µL of receptor media (to  
25 maintain 5 mL); (4) When all time points completed, disassemble the cells and dispose of all materials properly.

## Example 3

### Ex vivo Permeation Evaluation

An exemplary ex vivo permeation evaluation is as follows.

1. Tissue is freshly excised and shipped (e.g. overnight) at 4° C.
2. The tissue is processed and frozen at -20° C for up to three weeks prior to use.
3. The tissue is dermatomed to precise thickness.
4. Approximately 5 mL of receiving media is added to the receiving compartment. The media is selected to ensure sink conditions.
5. The tissue is placed in a franz diffusion cell, which includes a donor compound, a donor chamber, a membrane, sampling port, receptor chamber, stir bar, and a heater/circulator.
6. Approximately 0.5 mL of donor solution is applied or 8 mm circular film and wetted with 500µL PBS buffer.
7. Samples are taken from the receiving chamber at given intervals and replaced with fresh media.

#### **Example 4**

##### **Transbuccal delivery of doxepin**

The following is an exemplary permeation study on the transbuccal delivery of doxepin. The studies were conducted under a protocol approved by the Animal Experimentation Ethics Committee of the University of Barcelona (Spain) and the Committee of Animal Experimentation of the regional autonomous government of Catalonia (Spain). Female pigs 3–4-months-old were used. The porcine buccal mucosa from the cheek region was excised immediately after the pigs were sacrificed in the animal facility at Bellvitge Campus (University of Barcelona, Spain) using an overdose of sodium thiopental anesthesia. The fresh buccal tissues were transferred from the hospital to the laboratory in containers filled with Hank's solution. The remaining tissue specimens were stored at -80° C in containers with a PBS mixture containing 4% albumin and 10% DMSO as cryoprotective agents.

For the permeation studies, the porcine buccal mucosa was cut to 500 +/- 50 µm thick sheets, which contributes to the diffusional barrier (Buccal bioadhesive drug delivery — A promising option for orally less efficient drugs Sudhakar et al., *Journal of Controlled Release* 114 (2006) 15–40), using an electric dermatome (GA 630, Aesculap, Tuttlingen, Germany) and trimmed with surgical scissors in adequate pieces. The majority of the underlying connective tissue was removed with a scalpel.

Membranes were then mounted in specially designed membrane holders with a permeation orifice diameter of 9 mm (diffusion area 0.636 cm<sup>2</sup>). Using the membrane holder, each porcine buccal membrane was mounted between the donor (1.5 mL) and the receptor (6 mL) compartments with the epithelium side facing the donor chamber and the connective tissue region facing the receiver of static Franz-type diffusion cells (Vidra Foc Barcelona, Spain) avoiding bubbles formation.

Infinite dose conditions were ensured by applying 100 µL as donor solution of a saturated doxepin solution into the receptor chamber and sealed by Parafilm immediately to prevent water evaporation. Prior to conducting the experiments, the diffusion cells were incubated for 1 h in a water bath to equalize the temperature in all cells (37° +/- ° C). Each cell contained a small Teflon1 coated magnetic stir bar which was used to ensure that the fluid in the receptor compartment remained homogenous during the experiments.

Sink conditions were ensured in all experiments by initial testing of doxepin saturation concentration in the receptor medium. Samples (300 µL) were drawn via syringe from the center of the receptor compartment at pre-selected time intervals (0.1, 0.2, 0.3, 0.7, 1, 2, 3, 4, 5 and 6 h) for 6 h. The removed sample volume was immediately replaced with the same volume of fresh receptor medium (PBS; pH 7.4) with great care to avoid trapping air beneath the membrane. Additional details can be found in A. Gimemo, et al. Transbuccal delivery of doxepin: Studies on permeation and histological evaluation, *International Journal of Pharmaceutics* 477 (2014), 650-654, which is incorporated by reference herein.

## Example 5

### Oral transmucosal delivery

Porcine oral mucosal tissue has similar histological characteristics to human oral mucosal tissue (Heaney TG, Jones RS, Histological investigation of the influence of adult porcine alveolar mucosal connective tissues on epithelial differentiation. *Arch Oral Biol* 23 (1978) 713–717; Squier CA, and Collins P, The relationship between soft tissue attachment, epithelial downgrowth and surface porosity. *Journal of Periodontal Research* 16 (1981) 434-440). Lesch et al. (The Permeability of Human Oral Mucosa and Skin to Water, *J Dent Res* 68 (9), 1345-1349, 1989) reported that the water permeability of porcine buccal mucosa was not significantly different from human buccal mucosa but the floor of the mouth was more permeable in human

tissue than in pig tissue. Comparisons between fresh porcine tissue specimens and those stored at -80° C revealed no significant effect on permeability as a result of freezing. Porcine buccal mucosal absorption has been studied for a wide range of drug molecules both in vitro and in vivo (see, e.g., Table 1 of M. Sattar, Oral transmucosal drug delivery – current status and future prospects, *International Journal of Pharmaceutics* 471 (2014) 498-506), which is incorporated by reference herein. Typically, in vitro studies involve mounting excised porcine buccal tissue in Ussing chambers, Franz cells or similar diffusion apparatus. The in vivo studies described in the literature involve the application of the drug as a solution, gel or composition to the buccal mucosa of pigs followed by plasma sampling.

Nicolazzo et al. (The Effect of Various in Vitro Conditions on the Permeability Characteristics of the Buccal Mucosa, *Journal of Pharmaceutical Sciences* 92(12) (2002) 2399-2410) investigated the effects of various in vitro conditions on the permeability of porcine buccal tissue using caffeine and oestradiol as model hydrophilic and lipophilic molecules. Drug permeation in the buccal mucosa was studied using modified Ussing chambers. Comparative permeation studies were performed through full thickness and epithelial tissues, fresh and frozen tissues. Tissue integrity was monitored by the absorption of the fluorescein isothiocyanate (FITC)-labeled dextran 20 kDa (FD20) and tissue viability was assessed using an MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) biochemical assay and histological evaluation. Permeability through the buccal epithelium was 1.8-fold greater for caffeine and 16.7-fold greater for oestradiol compared with full thickness buccal tissue. Flux values for both compounds were comparable for fresh and frozen buccal epithelium although histological evaluation demonstrated signs of cellular death in frozen tissue. The tissue appeared to remain viable for up to 12 h postmortem using the MTT viability assay which was also confirmed by histological evaluation.

Kulkarni et al. investigated the relative contributions of the epithelium and connective tissue to the barrier properties of porcine buccal tissue. In vitro permeation studies were conducted with antipyrine, buspirone, bupivacaine and caffeine as model permeants. The permeability of the model diffusants across buccal mucosa with thickness of 250, 400, 500, 600, and 700 µm was determined. A bilayer membrane model was developed to delineate the relative contribution to the barrier function of the epithelium and the connective tissue. The relative contribution of the connective tissue region as a permeability barrier significantly increased with

increasing mucosal tissue thickness. A mucosal tissue thickness of approximately 500  $\mu\text{m}$  was recommended by the authors for in vitro transbuccal permeation studies as the epithelium represented the major permeability barrier for all diffusants at this thickness. The authors also investigated the effects of a number of biological and experimental variables on the permeability of the same group of model permeants in porcine buccal mucosa (Porcine buccal mucosa as in vitro model: effect of biological and experimental variables, Kulkarni et al., *J Pharm Sci.* 2010 99(3):1265-77). Significantly, higher permeability of the permeants was observed for the thinner region behind the lip (170–220  $\mu\text{m}$ ) compared with the thicker cheek (250–280  $\mu\text{m}$ ) region. Porcine buccal mucosa retained its integrity in Kreb's bicarbonate ringer solution at 4 °C for 24 h. Heat treatment to separate the epithelium from underlying connective tissue did not adversely affect its permeability and integrity characteristics compared with surgical separation.

Additional details can be found at M. Sattar, Oral transmucosal drug delivery – current status and future prospects, *International Journal of Pharmaceutics* 471 (2014) 498-506, which is incorporated by reference herein.

## Example 6

### Cryopreservation of buccal mucosa

Different areas of porcine buccal mucosa have different pattern of permeability, there is significantly higher permeability in the region behind the lips in comparison to cheek region, because in porcine buccal mucosa, the epithelium acts as a permeability barrier, and the thickness of the cheek epithelium is greater than that of the region behind the lips (Harris and Robinson, 1992). In exemplary permeation studies, the fresh or frozen porcine buccal mucosa from the same area was cut to  $500 \pm 50$   $\mu\text{m}$  thick sheets, which contributes to the diffusional barrier (Sudhakar et al., 2006), were obtained using an electric dermatome (model GA 630, Aesculap, Tuttlingen, Germany) and trimmed with surgical scissors in adequate pieces. All devices utilized were previously sterilized. The majority of the underlying connective tissue was removed with a scalpel. Membranes were then mounted in specially designed membrane holders with a permeation orifice diameter of 9 mm (diffusion area 0.63  $\text{cm}^2$ ). Using the membrane holder, each porcine buccal membrane was mounted between the donor (1.5 mL) and the receptor (6 mL) compartments with the epithelium facing the donor chamber and the connective tissue region facing the receiver of static Franz-type diffusion cells (Vidra Foc, Barcelona,

Spain) avoiding bubbles formation. Experiments were performed using PP, which has lipophilic characteristics ( $\log P = 1.16$ ; n-octanol/PBS, pH 7.4), ionisable ( $pK_a = 9.50$ ) and a MW= 259.3 g/mol, as a model drug (Modamio et al., 2000).

Infinite dose conditions were ensured by applying 300  $\mu$ L as a donor solution of a saturated solution of PP ( $C_0 = 588005 \pm 5852 \mu\text{g/mL}$  at  $37^\circ \pm 1^\circ\text{C}$ ,  $n = 6$ ), in PBS (pH 7.4) into the receptor chamber and sealed by Parafilm immediately to prevent water evaporation.

Prior to conducting the experiments, the diffusion cells were incubated for 1 h in a water bath to equilibrate the temperature in all cells ( $37^\circ \pm 1^\circ\text{C}$ ). Each cell contained a small Teflon coated magnetic stir bar which was used to ensure that the fluid in the receptor compartment remained homogenous during the experiments. Sink conditions were ensured in all experiments after initial testing of PP saturation concentration in the receptor medium.

Samples (300  $\mu$ L) were drawn via syringe from the center of the receptor compartment at the following time intervals: 0.25, 0.5, 1, 2, 3, 4, 5 and 6 h. The removed sample volume was immediately replaced with the same volume of fresh receptor medium (PBS; pH 7.4) with great care to avoid trapping air beneath the dermis. Cumulative amounts of the drug ( $\mu\text{g}$ ) penetrating the unit surface area of the mucosa membrane ( $\text{cm}^2$ ) were corrected for sample removal and plotted versus time (h). The diffusion experiments were carried out 27 times for the fresh and 22 times for the frozen buccal mucosa.

Additional details can be found at S. Amores, An improved cryopreservation method for porcine buccal mucosa in ex vivo drug permeation studies using Franz diffusion cells, *European Journal of Pharmaceutical Sciences* 60 (2014) 49–54.

## Example 7

### Permeation of quinine across sublingual mucosa sections

Since porcine and human oral membranes are similar in composition, structure and permeability measurements, porcine oral mucosa is a suitable model for human oral mucosa. Permeability across the porcine oral mucosa is not metabolically linked therefore it is not important for the tissue to be viable.

To prepare the porcine membranes, porcine floor of mouth and ventral (underside) tongue mucosa membranes were excised by blunt dissection using a scalpel. The excised mucosa were cut into approximately 1 cm squares and frozen on aluminium foil at  $-20^\circ\text{C}$  until used ( $<2$

weeks). For non-frozen ventral surface of porcine tongue, the mucosa was used in the permeation studies within 3 h of excision.

The permeability of the membranes to quinine was determined using all-glass Franz diffusion cells with a nominal receptor volume of 3.6mL and diffusional area of 0.2 cm<sup>2</sup>. The cell flanges were greased with high performance vacuum grease and the membranes mounted between the receptor and donor compartments, with the mucosal surface uppermost. Clamps were used to hold the membranes into position before the receptor compartments were filled with degassed phosphate buffered saline (PBS), pH 7.4. Micromagnetic stirrer bars were added to the receptor compartments and the complete cells were placed in a water bath at 37°C. The membranes were equilibrated with PBS applied to the donor compartments for 20 min before being aspirated with a pipette. Aliquots of 5 µL of the quinine solution or 100 µL of the saturated solutions of Q/2-HP-β-CD complex in different vehicles were applied to each of the donor compartments. In the study to determine the effect of saliva on the permeation of quinine across the ventral surface of the tongue, 100 µL of sterile saliva was added to the donor compartments before adding 5 µL of the quinine solution.

At 2, 4, 6, 8, 10 and 12 h, the receptor phases were withdrawn from the sampling ports and aliquots of 1mL samples were transferred to HPLC autosampler vials, before being replaced with fresh PBS stored at 37°C. Apart from the studies involving Q/2-HP-β-CD saturated solutions (where an infinite dose was applied at the start of the experiments), 5 µL of the respective quinine solution was reapplied to the donor phase up to 10 h. The purpose of this was to represent a hypothetical in-use finite dosing regimen based upon an interval of 2 h between doses. At least 3 replicates were carried out for each study.

Additional details can be found at C. Ong, Permeation of quinine across sublingual mucosa, in vitro, *International Journal of Pharmaceutics* 366 (2009) 58–64.

## 25 **Example 8**

### **Ex-Vivo Initial Study – Form of the API**

In this example, the permeation of Epinephrine Base was tested – solubilized in situ vs. the inherently soluble Epinephrine Bitartrate and no differences were found. Epinephrine Bitartrate was selected for further development based on ease of processing. Flux was derived as slope of the amount permeated as a function of time. Steady state flux extrapolated from the

plateau of flux vs time curve multiplied by the volume of receiver media. The graph in **Figure 2A** shows average amount permeated vs. time, with 8.00 mg/mL Epinephrine bitartrate and 4.4 mg/mL Epinephrine base solubilized. The graph in **Figure 2B** shows average flux vs. time, with 8.00 mg/mL Epinephrine bitartrate and 4.4 mg/mL Epinephrine base solubilized.

Donor Solution	Average Steady State Flux (ug/cm <sup>2</sup> *min)
Epinephrine Base (conc 4.4mg/mL)	0.512
Epinephrine Bitartrate (conc 8.00mg/mL)	0.466

### Example 9

#### Concentration dependence on permeation/flux

In this study, ex-vivo permeation of Epinephrine Bitartrate as a function of concentration was studied. **Figure 3** shows ex-vivo permeation of epinephrine bitartrate as a function of concentration. The study compared concentrations of 4 mg/mL, 8 mg/mL, 16 mg/mL and 100 mg/mL. Results showed that increasing concentration resulted in increased permeation, and level of enhancement diminishes at higher loading. The study compared concentrations of 4 mg/mL, 8 mg/mL, 16 mg/mL and 100 mg/mL.

Donor Solution	Average Steady State Flux (ug/cm <sup>2</sup> *min)
Epinephrine Bitartrate (conc 4mg/mL)	0.167
Epinephrine Bitartrate (conc 8mg/mL)	0.466
Epinephrine Bitartrate (conc 16mg/mL)*	1.317
Epinephrine Bitartrate (conc 100mg/mL)	2.942

Donor Solution	Ratio of enhancement	Theoretical enhancement
Epinephrine Bitartrate (4.00mg/mL)	N/A	N/A
Epinephrine Bitartrate (8.00mg/mL)	2.8	2
Epinephrine Bitartrate (16.00mg/mL)	7.9	4
Epinephrine Bitartrate (100.00mg/mL)	17.6	25

### Example 10

#### Influence of pH

In this example, the permeation of Epinephrine Bitartrate as a function of solution pH was studied. In this example, acidic conditions were explored for the ability to promote stability.



The results showed that pH 5 was slightly more favorable as compared to pH 3. The inherent pH of epinephrine bitartrate in solution in the concentration ranges explored is 4.5-5. No pH adjustment with buffers was required.

5        **Figure 4** shows permeation of epinephrine bitartrate as a function of solution pH. Acidic conditions were explored to promote stability. The results compared Epinephrine Bitartrate pH 3 buffer and Epinephrine Bitartrate pH 5 buffer, and found that the Epinephrine Bitartrate pH 5 buffer was slightly favorable.

### **Example 11**

#### **Influence of enhancers on permeation of epinephrine**

10        In this example, the permeation of epinephrine to test for transmucosal delivery was studied as the amount permeated ( $\mu\text{g}$ ) vs. time (in minutes). The following enhancers were screened for concentration effects in a solution containing 16.00 mg/mL Epinephrine. The graph on **Figure 5** demonstrates the results of these enhancers as a function of time.

<b>Legend</b>	<b>Enhancer</b>	<b>Average Steady State Flux (<math>\mu\text{g}/\text{cm}^2 \cdot \text{min}</math>)</b>	<b>Percent Enhancement</b>
No Enhancer	None	1.317	N/A
Enhancer A	<b>3% Labrasol</b> Caprylocaproyl polyoxyl-8 glycerides	5.208	395
Enhancer B	<b>3% Propylene glycol</b> monocaprylate	2.385	181
Enhancer C	3% Polyglyceryl-3 oleate	1.482	112
Enhancer D	<b>3% Oleoyl polyoxyl-6</b> glycerides	0.281	21
Enhancer E	3% TDM	2.642	201
Enhancer F	3% SGDC	0.342	26
Enhancer G	<b>3% Lauroyl polyoxyl-32</b> glycerides	1.641	125
Enhancer H	3% Ethanol	0.163	12
Enhancer I	6% Ethanol	0.254	19
Enhancer J	6% Labrasol Caprylocaproyl polyoxyl-8 glycerides	4.444	337
Enhancer K	6% Polyglyceryl-3 oleate	0.306	23
Enhancer L	3% clove oil	8.216	624

Enhancers were selected and designed with functionality influencing different barriers in the mucosa. While all tested enhancers did improve the amount permeated over time, clove oil

and Labrasol, in particular have shown significantly and unexpectedly high enhancement of permeation.

8.00mg/0.500mL  
40mg/ strip  
no enhancer

Time (min)	set 2 (A,B,C) average amount permeated	std dev set 2 amount perm	set 2 (D,E,F) average flux ( $\mu\text{g}/\text{cm}^2 \cdot \text{min}$ )	std dev set 2	steady state flux average
30	0	0	0	0	
45	2.5	4.33012702	0.260416667	0.4510549	1.317274
60	5.5	7.08872344	0.3125	0.3125	
120	31.33333333	26.1549868	0.672743056	0.5050226	
180	72.66666667	58.215834	1.076388889	0.8496863	
240	112.1666667	80.1878004	1.028645833	0.5733604	
300	160.1666667	103.254943	1.25	0.6036108	
360	213.3333333	131.305306	1.384548611	0.7308311	

8.00mg/0.500mL  
40mg/ strip  
Labrasol

Time (min)	set 1 (A,B,C) average amount permeated ( $\mu\text{g}$ )	std dev set 1 amount perm	set 1 (A, B,C) average flux ( $\mu\text{g}/\text{cm}^2 \cdot \text{min}$ )	std dev set 1	steady state flux average
0	0	0	0	0	
30	0.5	0.8660254	0.026041667	0.0451055	5.208333
45	2.666666667	0.28867513	0.225694444	0.0601407	
60	4	1.80277564	0.138888889	0.1674245	
120	28	16.3935963	0.625	0.3836177	
180	98	53.3291665	1.822916667	0.9701176	
240	238.1666667	93.0017921	3.650173611	1.136722	
300	421.1666667	115.153521	4.765625	0.6675003	
360	638.1666667	130.709921	5.651041667	0.4732495	

8.00mg/0.500mL  
**40mg/strip**  
 capryol 90

Time (min)	set 2 (A,B,C) average amount permeated	std dev set 2 amount perm	set 2 (D,E,F) average flux (µg/mL*min)	std dev set 2	steady state flux average
0	0	0	0	0	
30	0.00	0	0	0	
45	0.00	0	0	0	1.931424
60	0.00	0	0	0	
120	9.17	5.79511288	0.238715278	0.1509144	
180	38.67	16.7655401	0.768229167	0.2864583	
240	88.50	30.2654919	1.297743056	0.4018216	
300	150.67	39.6936183	1.618923611	0.3269068	
360	236.83	51.9358579	2.243923611	0.4999616	

8.00mg/0.500mL  
**40mg/strip**  
 plurol oleique

Time (min)	set 2 (A,B,C) average amount permeated	std dev set 2 amount perm	set 2 (D,E,F) average flux (µg/mL*min)	std dev set 2	steady state flux average
0	0.8	1.78885438	0	0	
30	10.80	13.325727	0.520833333	0.7186273	
45	20.90	22.1624683	1.052083333	0.9356173	1.481771
60	33.00	30.8058436	1.260416667	0.9319861	
120	90.70	68.1951245	1.502604167	1.005753	
180	157.00	107.373763	1.7265625	1.0427891	
240	239.80	140.586539	2.15625	1.2085059	
300	285.60	184.236397	1.192708333	1.484335	
360	353.60	221.81676	1.770833333	0.993644	

8.00mg/0.500mL  
**40mg/strip**  
 TDM

Time (min)	set 2 (A,B,C) average amount permeated	std dev set 2 amount perm	set 2 (D,E,F) average flux (µg/mL*min)	std dev set 2	steady state flux average
0	0.00	0.00	0.00	0.00	
20	0.00	0.00	0.00	0.00	
40	3.00	2.43	0.23	0.32	2.642144
60	8.83	4.86	0.46	0.35	
120	41.33	15.08	0.85	0.49	
180	99.75	30.17	1.52	0.79	
240	179.92	48.30	2.09	0.98	
300	276.92	72.35	2.53	1.19	
360	382.83	102.02	2.76	1.38	

8.00mg/0.500mL  
40mg/strip  
SGDC

Time (min)	set 2 (A,B,C) average amount permeated	std dev set 2 amount perm	set 2 (D,E,F) average flux (µg/mL*min)	std dev set 2	steady state flux average
0	0	0	0	0	
30	0.00	0	0	0	
45	0.67	1.30384048	0.069444444	0.1261521	0.341797
60	1.58	1.94935887	0.095486111	0.1063147	
120	7.00	9.44325156	0.141059028	0.1910856	
180	16.17	22.0323626	0.238715278	0.316132	
240	28.58	37.6191441	0.323350694	0.3977149	
300	43.00	54.3927844	0.375434028	0.4112124	
360	54.83	65.7976063	0.308159722	0.3008536	

8.00mg/0.500mL  
40mg/strip  
Labrafil

Time (min)	set 2 (A,B,C) average amount permeated	std dev set 2 amount perm	set 2 (D,E,F) average flux (µg/mL*min)	std dev set 2	steady state flux average
0	0.8	1.15108644	0	0	
30	1.10	1.51657509	0.015625	0.0232924	
45	1.10	1.51657509	0	0	0.28125
60	1.10	1.51657509	0	0	
120	4.00	4.89897949	0.075520833	0.0984775	
180	9.10	10.9167303	0.1328125	0.1671035	
240	15.20	18.7169709	0.158854167	0.2034753	
300	25.70	29.8487856	0.2734375	0.2910091	
360	36.80	43.3093523	0.2890625	0.3532943	

8.00mg/0.500mL  
40mg/strip  
Gelucire 44/14

Time (min)	set 2 (A,B,C) average amount permeated	std dev set 2 amount perm	set 2 (D,E,F) average flux (µg/mL*min)	std dev set 2	steady state flux average
0	0	0	0	0	
20	0.33	0.89442719	0.026041667	0.0637888	
40	3.83	5.94138031	0.2734375	0.378725	1.629774
60	11.50	17.1850225	0.598958333	0.8405853	
120	41.58	48.5059275	0.783420139	0.8042794	
180	91.92	82.5124233	1.310763889	0.9525224	
240	150.17	118.949569	1.516927083	0.9914576	
300	217.50	158.792947	1.753472222	1.0756081	
360	275.33	189.967563	1.506076389	0.9083155	

8.00mg/0.500mL  
40mg/strip  
clove oil

Time (min)	set 2 (A,B,C) average amount permeated	std dev set 2 amount perm	set 2 (D,E,F) average flux ( $\mu\text{g}/\text{cm}^2 \cdot \text{min}$ )	std dev set 2	steady state flux average
0	0	0	0	0	
20	0	0	0	0	
40	28.66666667	27.360251	2.239583333	2.1375196	8.270399
60	96.5	79.5424415	5.299479167	4.0954816	
120	389.6666667	278.072533	7.634548611	5.2070528	
180	688.6666667	451.678628	7.786458333	4.5210426	
240	1009.166667	603.252089	8.346354167	3.9590828	
300	1333.5	759.653046	8.446180556	4.1168559	
360	1644.333333	878.2762	8.094618056	3.2301203	

8.00mg/0.500mL  
40mg/strip  
3% Labrasol  
+1%TDM

Time (min)	set 2 (A,B,C) average amount permeated	std dev set 2 amount perm	set 2 (D,E,F) average flux ( $\mu\text{g}/\text{mL} \cdot \text{min}$ )	std dev set 2	steady state flux average
0	0	0	0	0	
20	0	0	0	0	3.161892
40	1.666666667	2.88675135	0.130208333	0.2255274	
60	6.833333333	11.8356805	0.403645833	0.6991351	
120	68.83333333	92.6907942	1.614583333	2.1084505	
180	103.6666667	101.539812	0.907118056	0.3351021	
240	180	130.184484	1.987847222	0.7476876	
300	291.5	149.81572	2.903645833	0.5193664	
360	422.8333333	164.032263	3.420138889	0.5530917	

## Example 12

### 5 Impact of enhancers on epinephrine release

Release profiles of epinephrine were studied to determine the impact of enhancers (Labrasol and clove oil) on epinephrine release. **Figure 6A** shows the epinephrine release from different polymer platforms. **Figure 6B** shows the impact of enhancers on epinephrine release. The results showed that the amount permeated leveled off after about 40 minutes to be between approximately 3250 and 4250  $\mu\text{g}$ . The tested enhancers were shown not to restrict the release of epinephrine from the matrix.

**Example 13****Accelerated stability**

The stabilizer loading variants were tested.

	Formulation 10	Formulation 10 with 0.25% Stabilizer	Formulation 10 with 1% Stabilizer
Time (weeks) @ 40°C/75% R.H.	EPI mg/film	EPI mg/film	EPI mg/film
0	39.3	37.9	38.3
2	35.2	36.8	34.7
4	38.2	36.8	36.2
8	37.7	35.6	35.1
12	36.1	35.4	35.1

5 **Example 14****Impact of Enhancer**

A pharmacokinetic model in the male Yucatan, miniature swine was studied. The graph on **Figure 7** shows the results of a pharmacokinetic model in the male Yucatan, miniature swine. The study compares a 0.3 mg EpiPen, a 0.12 mg Epinephrine IV and a placebo.

10 The impact of no enhancer is shown in **Figure 8** on the concentration profiles of a 0.3 mg EpiPen and a 40 mg Epinephrine film with no enhancer

The impact of enhancer 3% Labrasol is shown in **Figure 9**, which shows the impact of Enhancer A (Labrasol) on the concentration profiles of a 40 mg Epinephrine film vs. a 0.3 mg EpiPen. **Figure 10** shows the impact of Enhancer L (clove oil) on the concentration profiles of  
15 two 40 mg Epinephrine films (10-1-1) and (11-1-1) vs. a 0.3 mg EpiPen.

In addition, the influence of film dimensions and impact of clove oil (3%) is also shown in **Figure 11**. This study was carried out comparing 0.30 mg EpiPen (n=4), a 40 mg Epinephrine Film (10-1-1) (n=5) and a 40 mg Epinephrine Film (11-1-1) (n=5). The concentration vs. time profiles followed sublingual or intramuscular epinephrine administration to male miniature swine.

Studies were performed to vary the ratio of epinephrine to an enhancer. These studies were also concentration vs. time profiles following sublingual or intramuscular epinephrine administration to male miniature swine. Varying the ratio of Epinephrine to clove oil (Enhancer L) produced the results shown in **Figure 12**. This study was carried out comparing 0.30 mg EpiPen (n=4), a 40 mg Epinephrine Film (12-1-1) (n=5) and a 20 mg Epinephrine Film (13-1-1) (n=5).

### Example 15

A varying dose was carried out in constant matrix with enhancer Labrasol (3%) and clove oil (3%) are shown in **Figures 13** and **14** respectively. The study in **Figure 13** was carried out comparing 0.30 mg EpiPen (n=4), a 40 mg Epinephrine Film (18-1-1) (n=5) and a 30 mg Epinephrine Film (20-1-1) (n=5). The study in **Figure 14** was carried out comparing 0.30 mg EpiPen (n=4), a 40 mg Epinephrine Film (19-1-1) (n=5) and a 30 mg Epinephrine Film (21-1-1) (n=5). These studies were also concentration vs. time profiles following sublingual or intramuscular epinephrine administration to male miniature swine.

### Example 16

A pharmacokinetic model in the male miniature swine was studied to determine the impact of an enhancer (farnesol) on epinephrine concentration over time. The graph on **Figure 15** shows the epinephrine plasma concentration (in ng/mL) as a function of time (in minutes) following sublingual or intramuscular administration of a farnesol permeation enhancer. This study compares a 0.3 mg EpiPen (n=3), a 30 mg Epinephrine Film 31-1-1 (n=5) and a 30 mg Epinephrine Film 32-1-1 (n=5) each Epinephrine Film being formulated with a farnesol enhancer. As shown in this figure, the 31-1-1 film demonstrates enhanced stability of epinephrine concentration starting at about 30-40 minutes until approximately 130 minutes.

The graph in **Figure 16** is taken from the same study as Figure 17, but shows exclusively the data points comparing the 0.3 mg EpiPen against the 30 mg Epinephrine Film 31-1-1 (n=5).

The graph in **Figure 17** is taken from the same study as Figure 17, but shows exclusively the data points comparing the 0.3 mg EpiPen against the 30 mg Epinephrine Film 32-1-1 (n=5).

### Example 17

Referring to **Figure 18**, this graph shows a pharmacokinetic model in the male miniature swine was studied to determine the impact of an enhancer (farnesol) on epinephrine



concentration over time following sublingual or intramuscular administration. The epinephrine plasma concentration (in ng/mL) is shown as a function of time (in minutes) following sublingual or intramuscular administration of a farnesol permeation enhancer in Epinephrine films. The study compared data from three 0.3 mg Epipens against five 30 mg Epinephrine films (32-1-1). The data shows the Epinephrine films film having enhanced stability of epinephrine concentration starting at about 20-30 minutes until approximately 130 minutes.

### Example 18

In one embodiment, an epinephrine pharmaceutical composition film can be made with the following formulation:

	<b>Formulation A</b>		
<b>MATERIAL</b>	<b>WT % dry</b>	<b>WT % wet</b>	<b>mg/Strip</b>
EPINEPHRINE bitartrate	46.40	18.56	54.56
hydroxypropylmethyl cellulose	11.54	4.61	13.57
polyvinyl pyrrolidone	27.92	11.17	32.84
Glycerol monooleate	0.58	0.23	0.68
Polyethylene Oxide	1.16	0.46	1.36
Polysorbate	0.58	0.23	0.68
Phytoextract	9.98	3.99	9.97
Stabilizer	0.12	0.05	0.14
Buffer	0.58	0.23	0.68
Artificial sweetener	1.16	0.46	1.36
Linoleic acid	0.0037	0.00	0.00
Farnesol			
Yellow # 5			
<b>TOTAL</b>	<b>100.00</b>	<b>40.00</b>	<b>115.84</b>

## Example 19

An epinephrine pharmaceutical film compositions was made with the following formulation:

	<b>Formulation B</b>		
<b>MATERIAL</b>	<b>WT % dry</b>	<b>WT % wet</b>	<b>mg/Strip</b>
EPINEPHRINE bitartrate	46.17	18.47	54.29
Hydroxypropylmethyl cellulose	11.48	4.59	13.50
Polyvinyl pyrrolidone	27.78	11.11	32.67
Glycerol monooleate	0.58	0.23	0.68
Polyethylene Oxide	1.15	0.46	1.35
Polysorbate	0.58	0.23	0.68
Phytoextract	9.93	3.97	9.92
Stabilizer	0.12	0.05	0.14
Buffer	0.58	0.23	0.68
Artificial sweetener	1.15	0.46	1.35
Linoleic acid	0.50	0.20	0.59
Farnesol			
Yellow # 5			
<b>TOTAL</b>	<b>100.00</b>	<b>40.00</b>	<b>115.85</b>

## Example 20

In another embodiment, pharmaceutical film compositions were made with the following formulation:

5

	<b>Formulation C</b>		
<b>MATERIAL</b>	<b>WT % dry</b>	<b>WT % wet</b>	<b>mg/Strip</b>
EPINEPHRINE bitartrate	46.35	18.54	54.51
Hydroxypropylmethyl cellulose	11.53	4.61	13.55
Polyvinyl pyrrolidone	27.90	11.16	32.80
Glycerol monooleate	0.58	0.23	0.68
Polyethylene oxide	1.16	0.46	1.36
Polysorbate	0.58	0.23	0.68
Phytoextract	9.97	3.99	9.96
Stabilizer	0.12	0.05	0.14
Buffer	0.58	0.23	0.68
Artificial sweetener	1.16	0.46	1.36
Linoleic acid			
Farnesol	0.10	0.04	0.06
Yellow # 5			
<b>TOTAL</b>	<b>100.00</b>	<b>40.00</b>	<b>115.78</b>

## Example 21

In another embodiment, pharmaceutical film compositions were made with the following formulation:

5

	<b>Formulation D</b>		
<b>MATERIAL</b>	<b>WT % dry</b>	<b>WT % wet</b>	<b>mg/Strip</b>
EPINEPHRINE bitartrate	46.07	18.43	54.52
Hydroxypropylmethyl cellulose	11.46	4.58	13.56
Polyvinyl pyrrolidone	27.73	11.09	32.81
Glycerol monooleate	0.57	0.23	0.68
Polyethylene oxide	1.15	0.46	1.36
Polysorbate	0.57	0.23	0.68
Phytoextract	9.91	3.96	9.96
Stabilizer	0.11	0.05	0.14
Buffer	0.57	0.23	0.68
Artificial sweetener	1.15	0.46	1.36
Linoleic acid	0.10	0.04	0.06
Farnesol	0.50	0.20	0.29
Yellow # 5	0.10	0.04	0.06
<b>TOTAL</b>	<b>100.00</b>	<b>40.00</b>	<b>116.16</b>

## Example 22

Referring to **Figure 19**, this graph shows a pharmacokinetic model (logarithmic scale) in the male miniature swine studied to determine the impact of an enhancer (6% clove oil and 6% Labrasol) on epinephrine plasma concentration over time following sublingual or intramuscular administration. The epinephrine plasma concentration (in ng/mL) is shown as a function of time

10

(in minutes) following sublingual or intramuscular administration of a farnesol permeation enhancer in Epinephrine films. The data shows the Epinephrine films film having enhanced stability of epinephrine concentration starting at just after the 10 minute time point through about 30 minutes, and until approximately 100 minutes.

5 Referring to **Figure 20**, this graph shows a pharmacokinetic model of the Epinephrine film formulation in the male miniature swine as referenced in **Figure 19** compared against the average data collected from a 0.3 mg Epipen (indicated in diamond data points). As the data indicates, the average plasma concentration for the 0.3 mg Epipen peaked between 0.5 and 1 ng/mL. By contrast, the Epinephrine film formulation peaked between 4 and 4.5 ng/mL.

10 Example 23

Referring to **Figure 21**, this graph shows a pharmacokinetic model in the male miniature swine studied to determine the impact of an enhancer (9% clove + 3% Labrasol) on epinephrine concentration over time following sublingual or intramuscular administration across 7 animal models. The general peak concentration was achieved between 10-30 minutes.

15 All references cited herein are hereby incorporated by reference herein in their entirety.

**Example 23**

In one embodiment, a dipivefrin pharmaceutical composition film can be made with the following formulation:

<b>MATERIAL</b>	<b>WT % dry</b>	<b>mg/Strip</b>
Dipivefrin	3.45	<i>3.297</i>
HPMC E15	23.22	<i>22.165</i>
PVP K90	<i>57.57</i>	<i>54.959</i>
GMO	0.50	<i>0.476</i>
PEO N10	0.50	<i>0.476</i>
PEG400	9.25	<i>8.830</i>
clove oil	3.00	<i>2.437</i>
sodium citrate	0.50	<i>0.476</i>
sucralose	1.00	<i>0.952</i>
labrasol	1.00	<i>0.956</i>
green #3	0.01	<i>0.010</i>
<b>TOTAL</b>	<b>100.00</b>	<b>95.03</b>

**Example 24**

In another embodiment, a dipivefrin pharmaceutical composition film can be made with the following formulation:

<b>MATERIAL</b>	<b>WT % dry</b>	<b>mg/Strip</b>
Dipivefrin	6.00	<i>6.602</i>
HPMC E15	21.22	<i>23.350</i>
PVP K90	51.52	<i>56.690</i>
GMO	0.50	<i>0.548</i>
PEO N10	0.50	<i>0.548</i>
PEG400	9.25	<i>10.179</i>
clove oil	3.00	<i>2.809</i>
citric acid	3.00	<i>3.301</i>
sodium citrate	2.00	<i>2.201</i>
sodium metabisulfite	1.00	<i>1.100</i>
sucralose	1.00	<i>1.097</i>
labrasol	1.00	<i>1.102</i>
green #3	0.01	<i>0.011</i>
<b>TOTAL</b>	<b>100.00</b>	<b>109.54</b>

**Example 25**

In another embodiment, a dipivefrin pharmaceutical composition film can be made with the following formulation:

<b>MATERIAL</b>	<b>WT % dry</b>	<b>mg/Strip</b>
Dipivefrin	10.50	<i>13.204</i>
HPMC E15	20.22	<i>25.427</i>
PVP K90	48.02	<i>60.385</i>
GMO	0.50	<i>0.627</i>
PEO N10	0.50	<i>0.627</i>
PEG400	9.25	<i>11.633</i>
clove oil	3.00	<i>3.211</i>
citric acid	3.00	<i>3.773</i>
sodium citrate	2.00	<i>2.515</i>
sodium metabisulfite	1.00	<i>1.258</i>
sucralose	1.00	<i>1.254</i>
labrasol	1.00	<i>1.259</i>
green #3	0.01	<i>0.013</i>
<b>TOTAL</b>	<b>100.00</b>	<b>125.18</b>



**Example 26**

In one study, the investigators compared the pharmacokinetics of epinephrine after Dipivefrin SL administration to other routes of administrations (Oral, SC and IV), specifically analyzing epinephrine bioavailability and conversion of dipivefrin to epinephrine.

Group	No. of Animals (Male)	Test Article	Dose Route	Target Dose Level (mg/animal)	Dipi Dose Conc. (mg/DF or mL)	Target Dose Amount (mL or DF/animal)
1	1	Placebo	SL	0	0 mg/DF	1 DF
2	5	Dipivefrin DF: Dip 16-1-1	SL	6	6 mg/DF	1 DF
3	3	Dipivefrin Solution	PO	6	0.6 mg/mL	10 mL
4	3	Dipivefrin solution (Dissolved SL Film)	PO	6	0.6 mg/mL	10 mL
5	4	Dipivefrin Solution	SC	22	22 mg/mL	1 mL
6	4	Dipivefrin Solution	IV	1	1 mg/mL	1 mL

The study compared various dose routes: sublingual (SL), per oral tablet (PO), subcutaneous (SC) and intravenous (IV). The PK Time-points (for All Groups): 0 (pre-dose), 2, 5, 10, 12, 15, 17, 20, 25, 30, 40, 60, 90 and 120 minutes and 3 hr, 4 hr, 6 hr and 8 hr post dose. An Oral Irritation assessment was performed (SL film group): Predose (0) and 24 hr postdose by Draize scoring. The dipivefrin film (DF) is an exemplary embodiment of the claimed pharmaceutical composition.

Referring to **Fig. 22A**, the data shows average epinephrine plasma concentration vs. time in 60 minutes. Referring to **Fig. 22B**, the data shows average epinephrine plasma concentration vs. time in 480 minutes. Surprisingly, the dipivefrin film showed ability to meet target C<sub>max</sub> of 0.2 ng/mL- 1.5 ng/mL in less than 30 minutes. The C<sub>max</sub> was shown to be 0.1 ng/mL- 2 ng/mL, 0.15 ng/mL-1.5 ng/mL, and 0.2 ng/mL- 1.0 ng/mL. The C<sub>max</sub> was shown to be greater than 0.1 ng/mL, greater than 0.15 ng/mL, greater than 0.2 ng/mL, greater than 0.4 ng/mL, greater than

0.5ng/ml, greater than 0.6 ng/ml, greater than 0.7 ng/ml and less than 2 ng/ml and less than 1.5 ng/ml.

The Tmax is shown in the range of 0-480 minutes, including 10-60 minutes, 20-40 minutes, 12-15 minutes, and 5-10 minutes. The Tmax has been shown to be less than 25  
5 minutes, less than 20 minutes, 15 minutes, less than 12 minutes, and less than 10 minutes.

Referring to **Fig. 23A**, the data shows average dipivefrin plasma concentration vs. time in 60 minutes. Referring to **Fig. 23A**, the data shows average dipivefrin plasma concentration vs. time in 480 minutes. The amount of dipivefrin is shown to decrease as epinephrine is being formed. This data shows a surprising ability of the subject film to meet a target Cmax of 0.2  
10 ng/ml- 1.5 ng/ml and a Tmax of less than 35 minutes. The Cmax is shown to be 0.1 ng/ml- 2 ng/ml, 0.15 ng/ml-25 ng/ml, 0.2 ng/ml- 1.0 ng/ml, 0.2 ng/ml -1.2 ng/ml, and 0.2 ng/ml - 1.3 ng/ml. The Cmax has been shown to be greater than 0.1 ng/ml, greater than 0.15 ng/ml, greater than 0.2 ng/ml, greater than 0.4ng/ml, greater than 0.5ng/ml, greater than 1.0ng/ml, greater than 1.2 ng/ml, and less than 3 ng/ml, less than 2 ng/ml and less than 1.5 ng/ml. The Tmax is shown  
15 in the range of 0-480 minutes, including 10-60 minutes, 20-40 minutes, 12-15 minutes, and 5-10 minutes. The Tmax has been shown to be less than 25 minutes, less than 20 minutes, 15 minutes, less than 12 minutes, and less than 10 minutes.

Referring to **Fig. 24**, the data shows that average plasma concentration of epinephrine (dipivefrin SL 16-1-1 E) in round data points and dipivefrin (dipivefrin SL-Dip 16-1-1 D) in  
20 square data points. This shows the amount of dipivefrin decreases as epinephrine is being formed.

Referring to **Fig. 25**, the graph shows the conversion of dipivefrin to epinephrine (SC and IV groups). The dashed lines indicate dipivefrin, and the solid lines indicate epinephrine.

	EPI AUC0-t	EPI Tmax (Min)	EPI Cmax (mean, ng/ml)	DIPI AUC0-t	DIPI Tmax (Min)	DIPI Cmax (mean, ng/ml)
Placebo SL	0	0	0	0	0	0
Dipi 9%C6 mg	197.4	180	0.75	12.26	30	1.14
Dipi Solution (6mg, PO)	41.4	120	0.28	0	0	0
Dipi Film Solution (6mg, PO)	24.2	12	0.24	0	0	0
Dipi Solution (22 mg, SC)	4220.0	180 (3 <sup>rd</sup> peak)	12.5	1505	5	15
Dipi Solution (1mg, IV)	146.4	2	7.62	53.24	2	11.7
%Bioavailability- Dipi solution SC (Relative to IV)	131.0%			128.5%		

The results showed no local irritation with the Dipivefrin SL film. The results also showed that dipivefrin was converted into Epinephrine rapidly-SC administration of dipivefrin had a depot effect-had the higher and prolonged epinephrine exposure compared to IV administration. The results showed that dipivefrin IV administration had a faster onset and maximum epinephrine exposure at 2 minutes and cleared from the system within 2 hours. The results indicate that oral administration showed minimal epinephrine exposure compared to other routes of administration (dipivefrin concentration was below the detection limit). In short, surprisingly, no difference was found between dipivefrin solution and dipivefrin film solution with permeation enhancers.

**Example 27**

In this investigation, the investigators studied the conversion of dipivefrin to epinephrine. The study adjusted three variables systemically: drug concentration, dose, and enhancer loading. The data was analyzed to identify speed to onset, Cmax, area under the plasma drug concentration-time curve (AUC) during the first 20-25 minutes.

Referring to **Fig. 26**, the data shows average average epinephrine profiles across all matrix studies. The time to initial peak average is within about 30 minutes, 25 minutes, and 20 minutes. The 6mg dipivefrin/6% clove film (dip 10-1-1) achieved the fastest average results.

10

		minutes									
	dose/clove	-10	5	10	12	15	17	20	25	30	average
Dip 4-1-2	3mg/3%				1	2	1			1	17.8
Dip 4-2-1	6mg/3%			2	1	1					11.75
Dip 10-1-1	6mg/6%		1	4							9
Dip 11-1-1	6mg/6%					1		2	2		21
Dip 11-2-1	9mg/6%					2			2	1	22
Dip 12-1-1	9mg/9%						1	2		1	21.75
Dip 12-2-1	12mg/9%				1	2		2			16.4
Dip 13-1-1	12mg/6%						1	2	2		21.4
Dip 14-1-1	12mg/6%						2	1	2		20.8

Referring to **Fig. 27**, the data shows additional data comparing plasma concentration of dipivefrin and epinephrine (ng/ml) vs. time in hours. A mean therapeutic window has shown to be achieved within 30 minutes or less, including individual averages in 20 minutes or less, and 15 minutes or less.

15

**Example 28**

An investigation yielded results that validate the receptor interactor antagonism needed to drive greater levels of epinephrine transmucosally. Preclinical results comparing the 30mg formulation of epinephrine sublingual film (ESF) versus a pretreatment of a phentolamine (a reversible nonselective  $\alpha$ -adrenergic antagonist) at the site of application 10 min prior to dosing (phen 0.10 mg/ESF). The pretreatment showed that improved plasma concentration levels within a therapeutic window of 30 minutes or less, 25 minutes or less, and 20 minutes or less.

	Tmax (min)	Cmax (ng/mL)	AUC (min*ng/mL)
Epipen	35	1.52 + 0.857	74.48 + 22.94
ESF	25	0.99 + 0.64	42.96 + 11.04
Phen 0.10 mg/ESF	25	7.68 + 3.89	161.22 + 70.24

Referring to **Fig. 28**, this graph shows the epinephrine plasma concentration vs. time profile in a follow-up study that examined the loading of phentolamine and how it influences the absorption of epinephrine. For this study, 30 mg epinephrine sublingual films (ESF) were used. The results show that the loading is dose dependent. The results are shown in the graph and summarized below:

	Tmax (min)	Cmax (ng/mL)	AUC (min*ng/mL)
Epipen	35	2.04 + 2.13	90.35 + 105.0
Phen 0.25 mg/ESF	25	1.93 + 1.02	43.18 + 57.5
Phen 0.10 mg/ESF	27.5	1.19 + 0.60	45.12 + 27.24

As shown in the graph and indicated in the above data, a therapeutic window can be seen for ESF within 30 minutes or less, 25 minutes or less, and 20 minutes or less.

Other embodiments are within the scope of the following claims.

**CLAIMS:**

What is claimed is:

1. A pharmaceutical composition, comprising:

a polymeric matrix;

5           pharmaceutically active component including epinephrine or its prodrug in the polymeric matrix; and

an adrenergic receptor interacter.

2. The pharmaceutical composition according to claim 1, further comprising a permeation  
10 enhancer.

3. The pharmaceutical composition according to claim 1, wherein the composition is a film further comprising a polymeric matrix, the pharmaceutically active component being contained in the polymeric matrix.  
15

4. The pharmaceutical composition according to claim 2, wherein the permeation enhancer includes a phenylpropanoid.

5. The pharmaceutical composition according to claim 2, wherein the permeation enhancer  
20 includes farnesol or Labrasol.

6. The pharmaceutical composition according to claim 2, wherein the permeation enhancer includes linoleic acid.

25 7. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is a film further comprising a polymeric matrix, the pharmaceutically active component being contained in the polymeric matrix.

8. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is a chewable or gelatin based dosage form, spray, gum, gel, cream, tablet, liquid or film.

5 9. The pharmaceutical composition according to claim 4, wherein the phenylpropanoid is eugenol or eugenol acetate.

10. The pharmaceutical composition according to claim 4, wherein the phenylpropanoid is a cinnamic acid, cinnamic acid ester, cinnamic aldehyde or hydrocinnamic acid.

10

11. The pharmaceutical composition according to claim 4, wherein the phenylpropanoid is chavicol.

12. The pharmaceutical composition according to claim 4, wherein the phenylpropanoid is safrole.

15

13. The pharmaceutical composition according to claim 1, wherein the adrenergic receptor interacter is a phytoextract.

20 14. The pharmaceutical composition according to claim 13, wherein the phytoextract further includes an essential oil extract of a clove plant.

15. The pharmaceutical composition according to claim 13, wherein the phytoextract further includes an essential oil extract of a leaf of a clove plant.

25

16. The pharmaceutical composition according to claim 13, wherein the phytoextract further includes an essential oil extract of a flower bud of a clove plant.

17. The pharmaceutical composition according to claim 13, wherein the phytoextract further includes an essential oil extract of a stem of a clove plant.

30

18. The pharmaceutical composition according to claim 13, wherein the phytoextract is synthetic or biosynthetic.

19. The pharmaceutical composition according to claim 13, wherein the phytoextract further  
5 includes 40-95% eugenol.

20. The pharmaceutical composition according to claim 1, wherein the adrenergic receptor interacter includes a terpenoid, terpene or a sesquiterpene.

10 21. The pharmaceutical composition according to claim 1, wherein the polymer matrix includes a polymer.

22. The pharmaceutical composition according to claim 21, wherein the polymer is a water soluble polymer.

15 23. The pharmaceutical composition according to claim 21, wherein the polymer includes a polyethylene oxide.

24. The pharmaceutical composition according to claim 21, wherein the polymer includes a  
20 cellulosic polymer is selected from the group of: hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, methylcellulose and carboxymethyl cellulose.

25 25. The pharmaceutical composition according to claim 21, wherein the polymeric matrix comprises a cellulosic polymer, polyethylene oxide and polyvinyl pyrrolidone, polyethylene oxide and a polysaccharide, polyethylene oxide, hydroxypropyl methylcellulose and a polysaccharide, or polyethylene oxide, hydroxypropyl methylcellulose, polysaccharide and polyvinylpyrrolidone.

30 26. The pharmaceutical composition according to claim 21, wherein the polymeric matrix comprises at least one polymer selected from the group of: pullulan, polyvinyl pyrrolidone,



polyvinyl alcohol, sodium alginate, polyethylene glycol, xanthan gum, tragacanth gum, guar gum, acacia gum, arabic gum, polyacrylic acid, methylmethacrylate copolymer, carboxyvinyl copolymers, starch, gelatin, ethylene oxide-propylene oxide co-polymers, collagen, albumin, poly-amino acids, polyphosphazenes, polysaccharides, chitin, chitosan, and derivatives thereof.

5

27. The pharmaceutical composition according to claim 1, further comprising a stabilizer.

28. The pharmaceutical composition according to claim 1, wherein the polymeric matrix comprises a dendritic polymer or a hyperbranched polymer.

10

29. A method of making a pharmaceutical composition comprising:

combining an adrenergic receptor interacter with a pharmaceutically active component including epinephrine or its prodrug and

forming a pharmaceutical composition including the adrenergic receptor interacter and the pharmaceutically active component.

15

30. A device comprising

a housing that holds an amount of a pharmaceutical composition, comprising:

a polymeric matrix;

a pharmaceutically active component including epinephrine or its prodrug in the polymeric matrix; and

20

a phenylpropanoid and/or a phytoextract; and

an opening that dispenses a predetermined amount of the pharmaceutical composition.

25

31. A pharmaceutical composition, comprising:

a polymeric matrix;

a pharmaceutically active component including epinephrine or its prodrug in the polymeric matrix; and

30

an aporphine alkaloid interacter.

32. A pharmaceutical composition, comprising:

a polymeric matrix;  
a pharmaceutically active component including epinephrine or its prodrug in the polymeric matrix; and  
a vasodilator interacter.

5 33. A pharmaceutical composition, comprising:

a polymeric matrix;  
a pharmaceutically active component including epinephrine or its prodrug in the polymeric matrix; and  
an interacter that creates increased blood flow or enables a flushing of the tissue to  
10 modify transmucosal uptake of the pharmaceutically active component.

34. A pharmaceutical composition, comprising:

a polymeric matrix;  
a pharmaceutically active component including epinephrine or its prodrug in the polymeric matrix; and  
15 an interacter that has a positive or negative heat of solution which are used as aids to modify transmucosal uptake.

35. A pharmaceutical composition, comprising:

a polymeric matrix;  
a pharmaceutically active component including epinephrine or its prodrug in the  
20 polymeric matrix; and  
an interacter, the composition contained in a multilayer film having at least one side where the edges are coterminous.

36. A method of treating a medical condition comprising

administering an effective amount of a pharmaceutical composition comprising:  
25 a polymeric matrix;  
pharmaceutically active component including epinephrine or its prodrug in the polymeric matrix; and

an adrenergic receptor interacter.

37. The method of claim 35, wherein the prodrug is dipifevrin.

38. The method of claim 35, wherein the medical condition includes hypotension, cardiac arrest, heart failure, anaphylaxis, mydriasis, asystole, pulseless electrical activity, ventricular  
5 fibrillation, pulseless ventricular tachycardia, bradycardia, arrhythmia, or asthma exacerbation.

39. The pharmaceutical composition according to claim 1, wherein the prodrug is dipifevrin.

40. The method of claim 29, wherein the prodrug is dipifevrin.

41. The device of claim 30, wherein the prodrug is dipifevrin.

42. The pharmaceutical composition according to claim 31, wherein the prodrug is  
10 dipifevrin.

43. The pharmaceutical composition according to claim 32, wherein the prodrug is dipifevrin.

44. The pharmaceutical composition according to claim 33, wherein the prodrug is dipifevrin.

15 45. The pharmaceutical composition according to claim 34, wherein the prodrug is dipifevrin.

46. The pharmaceutical composition according to claim 35, wherein the prodrug is dipifevrin.

47. A pharmaceutical film, comprising:

20 a polymeric matrix;

pharmaceutically active component including epinephrine or its prodrug contained in the polymeric matrix

and


an adrenergic receptor interacter,  
the pharmaceutical film having a Tmax of 5-60 minutes, and a Cmax of 0.1 ng/ml-2  
ng/ml.

5    48.    The pharmaceutical film of claim 47, wherein the Tmax is 40 minutes or less and wherein  
the Cmax is 0.1 ng/ml or greater.

49.    The pharmaceutical film of claim 47, wherein the Tmax is 35 minutes or less and wherein  
the Cmax is 0.15 ng/ml or greater.

10

50.    The pharmaceutical film of claim 47, wherein the Tmax is 30 minutes or less and wherein  
the Cmax is 0.2 ng/ml or greater.



**FIG. 1A**






FIG. 1B



### Ex-Vivo Permeation of Epinephrine Bitartrate as a Function of Concentration





FIG. 3



**FIG. 4**




FIG. 5




FIG. 6A






FIG. 6B

**Epinephrine Plasma Concentration vs Time Profiles Following an Intravenous or Intramuscular Epinephrine Administration to Male Miniature Swine**



**FIG. 7**

**Epinephrine Plasma Concentration vs Time Profiles Following a Sublingual or Intramuscular Epinephrine Administration to Male Miniature Swine**



**FIG. 8**

Epinephrine Plasma Concentration vs Time Profiles Following a Sublingual or Intramuscular Epinephrine Administration to Male Miniature Swine






FIG. 9

**Epinephrine Plasma Concentration vs Time Profiles Following Sublingual or Intramuscular Epinephrine Administration to Male Miniature Swine**



**FIG. 10**


**Epinephrine Plasma Concentration vs Time Profiles Following Sublingual or Intramuscular Epinephrine Administration to Male Miniature Swine**



**FIG. 11**




**Epinephrine Plasma Concentration vs Time Profiles Following Sublingual or Intramuscular Epinephrine Administration to Male Miniature Swine**




**FIG. 12**

**Epinephrine Plasma Concentration vs Time Profiles Following Sublingual or Intramuscular Epinephrine Administration to Male Miniature Swine**



**FIG. 13**

**Epinephrine Plasma Concentration vs Time Profiles Following Sublingual or Intramuscular Epinephrine Administration to Male Miniature Swine**



Epinephrine Plasma Concentration vs Time Profiles Following a Sublingual or Intramuscular Administration to Male Miniature Swine




FIG. 15




FIG. 16





FIG. 17


**Epinephrine Plasma Concentration vs Time  
Profiles Following a Sublingual  
or Intramuscular Administration  
to Male Miniature Swine**

- 0.3 mg/kg Epipen 2M1
- 0.3 mg/kg Epipen 2M3
- 0.3 mg/kg Epipen 2M4
- ▽— 30 mg Epinephrine Film 32-1-1 4M1
- ▽— 30 mg Epinephrine Film 32-1-1 4M2
- ▽— 30 mg Epinephrine Film 32-1-1 4M3
- ▽— 30 mg Epinephrine Film 32-1-1 4M4
- ▽— 30 mg Epinephrine Film 32-1-1 4M5



**FIG. 18**

**Epinephrine Plasma Concentration vs Time Profiles Following a Sublingual Administration to Male Miniature Swine**




—△— 40 mg Epinephrine Film 67-1-1 (n=7) \*


\* Epinephrine Film Formulation also Contains 6% Clove Oil and 6% Labrasol

**FIG. 19**



**Formulation 67-40mg epi with 6% Clove + 6% Labrasol****FIG. 20**


**Epinephrine Plasma Concentration vs Time Profiles Following a Sublingual or Intramuscular Administration to Male Miniature Swine**



\* Epinephrine Film Formulation also Contains 9% Clove Oil and 3% Labrasol

**FIG. 21**

FIG. 22A



Average Epinephrine Plasma Concentration vs. Time Profile (60 Min)

FIG. 22B




FIG. 23A





FIG. 23B

Average Dipivefrin Plasma Concentration vs. Time (480 min)



Dipivefrin SL Dip 16-1-1




FIG. 24

FIG. 25




FIG. 26

## Average Epinephrine and Dipivefrin Profiles Across All Matrix Studies




FIG. 27







FIG. 28

**Epinephrine Plasma Concentration vs Time Profiles Following a Sublingual or Intramuscular Administration to Male Miniature Swine**



## INTERNATIONAL SEARCH REPORT

International application No  
PCT/US2018/053042

A. CLASSIFICATION OF SUBJECT MATTER  
INV. A61K9/70 A61K31/085  
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 2017/192921 A1 (MONOSOL RX LLC [US]) 9 November 2017 (2017-11-09) page 1, line 14 - page 4, line 25 page 58 - page 61; examples 18-21 claims -----	1-50
X,P	WO 2017/192923 A1 (MONOSOL RX LLC [US]) 9 November 2017 (2017-11-09) page 1, line 18 - page 5, line 6 page 63 - page 66; examples 19-22 claims -----	1-50
X	US 2007/202163 A1 (RAWAS-QALAJI MUTASEM [CA] ET AL) 30 August 2007 (2007-08-30) paragraph [0111] - paragraph [0117] example 1 -----	1-50



Further documents are listed in the continuation of Box C.



See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

3 December 2018

Date of mailing of the international search report

11/12/2018

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040,  
Fax: (+31-70) 340-3016

Authorized officer

Muller, Sophie

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2018/053042

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2017192921 A1	09-11-2017	CA 3022840 A1	09-11-2017
		US 2017348251 A1	07-12-2017
		WO 2017192921 A1	09-11-2017
WO 2017192923 A1	09-11-2017	CA 3022797 A1	09-11-2017
		US 2017290776 A1	12-10-2017
		WO 2017192923 A1	09-11-2017
US 2007202163 A1	30-08-2007	US 2007202163 A1	30-08-2007
		WO 2008095284 A1	14-08-2008